Dexcom (DXCM) 10-K risk factor changes: FY2022 vs FY2021
The 2022-12-31 10-K against the 2021-12-31 one, compared heading by heading and sentence by sentence.
Item 1A191 rewritten102 added105 removed905 unchanged
All filing items908 rewritten551 added376 removed2,355 unchanged
Sentence counts leave out repeated page headers and footers. 5 of those lines differ and are listed apart under each item.
Summary
counted, not written
- Item 1A lists 78 risk factor headings: 4 new, 1 reworded and 73 unchanged since FY2021. 2 headings from FY2021 no longer appear.
- Sentence by sentence, 551 added, 376 removed, 908 rewritten and 2,355 unchanged across 12 items that differ.
- Not counted above: 5 repeated page header or footer lines also differ. They are listed apart under each item.
New Item 1A headings (4)
- causes, or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.”
- Environmental, social and governance, or ESG, regulations, policies and provisions could expose us to numerous risks.
- Our business could be negatively impacted by evolving expectations and challenges relating to implementing ESG initiatives, setting ESG-related goals, collecting ESG-related data, and disclosing ESG-related information.
- We may be adversely affected by the effects of inflation.
Removed Item 1A headings (2)
- Environmental, social and corporate governance, or ESG regulations, policies and provisions may make our supply chain more complex and may adversely affect our relationships with customers.
- Our business could be negatively impacted by corporate citizenship and ESG matters and/or our reporting of such matters.
Reworded Item 1A headings (1)
- Although many third-party payors have adopted some form of coverage policy
[removed: on][added: for] continuous glucose monitoring devices, our products do not always have[removed: some form of][added: such] coverage, including simple broad-based contractual coverage, with third-party payors and we frequently experience administrative challenges in obtaining [added: coverage or] reimbursement for our[removed: customers.][added: products.] If we are unable to obtain adequately broad [added: coverage or] reimbursement[removed: at acceptable prices]for our products or any future products from third-party payors, our revenue may be negatively impacted.
A heading is new when no FY2021 heading matches it after ignoring case and punctuation, and reworded when it shares at least 60 percent of its words with one that went away. All current risk factor headings.
Sentences by item
23 items, with every count and a link to each item that changed
| Item | Added | Removed | Rewritten | Unchanged | Page headers and footers changed |
|---|---|---|---|---|---|
| Item 1A. RISK FACTORS | 102 | 105 | 191 | 905 | 0 |
| Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS | 39 | 23 | 82 | 126 | 2 |
| Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK | 6 | 4 | 8 | 15 | 0 |
| Item 1. BUSINESS | 87 | 71 | 106 | 459 | 1 |
| Item 3. LEGAL PROCEEDINGS | 0 | 0 | 1 | 5 | 0 |
| Cover and table of contents | 2 | 1 | 35 | 78 | 1 |
| Item 1B. UNRESOLVED STAFF COMMENTS | 0 | 0 | 0 | 1 | 0 |
| Item 2. PROPERTIES | 9 | 4 | 4 | 2 | 0 |
| Item 4. MINE SAFETY DISCLOSURES | 0 | 0 | 0 | 2 | 0 |
| Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES | 11 | 4 | 6 | 12 | 1 |
| Item 6. [RESERVED] | 0 | 0 | 0 | 0 | 0 |
| Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA | 0 | 0 | 1 | 2 | 0 |
| Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE | 0 | 0 | 0 | 1 | 0 |
| Item 9A. CONTROLS AND PROCEDURES | 1 | 5 | 9 | 34 | 0 |
| Item 9B. OTHER INFORMATION | 0 | 0 | 0 | 1 | 0 |
| Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS | 0 | 0 | 0 | 2 | 0 |
| Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE | 0 | 0 | 0 | 7 | 0 |
| Item 11. EXECUTIVE COMPENSATION | 0 | 0 | 0 | 1 | 0 |
| Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS | 0 | 0 | 0 | 1 | 0 |
| Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE | 0 | 0 | 0 | 2 | 0 |
| Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES | 0 | 0 | 0 | 2 | 0 |
| Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES | 3 | 35 | 30 | 22 | 0 |
| Item 16. FORM 10-K SUMMARY | 291 | 124 | 435 | 675 | 0 |
Underlined words on a shaded ground are new in FY2022; struck-through words were in FY2021. Sentences that are wholly new or wholly gone are labelled rather than marked.
Item 1A. RISK FACTORS
191 rewritten, 102 added, 105 removed, 905 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
We have experienced, and anticipate that we will continue to experience, decreasing prices for our products due to pricing pressure from managed care organizations and other third-party payors, increased market power of our payors, [removed: as the medical device industry consolidates,] and increased competition among suppliers, including manufacturing services [removed: providers.][added: providers, as the medical device industry consolidates.]
The [added: ongoing] COVID-19 pandemic may result in increased costs for manufacturing and outsourced services while also causing additional pressure to reduce the prices for our products if a recession or depression occurs and people are unable to afford our products.
We cannot predict the ultimate impact that the [added: ongoing] COVID-19 [removed: pandemic and its] [added: pandemic, economic conditions, or their] effects could have on our business operations, financial condition and cash flows.
We expect that the continuing cost reduction and containment measures may reduce the cost or utilization of health care products and could lead to patients being unable to obtain approval for coverage or payment from these third-party [removed: payors.][added: payors or to costs being shifted to patients for our products.]
Additionally, as a result of the [added: ongoing] COVID-19 pandemic, [added: and economic slowdown,] some customers have [added: lost access] and others may lose access to their private health insurance plan if they lose their job, and an impact to job status may extend for a prolonged period of time, beyond possible coverage periods through COBRA, or where the cost to maintain coverage may not be affordable to our customer.
As most of our customers rely on third-party payors, including government programs and private health insurance plans, to cover the cost of our products, our customers may lose coverage [added: or reimbursement] for our products, which may harm our business and results of operations.
Although many third-party payors have adopted some form of coverage policy [removed: on] [added: for] continuous glucose monitoring devices, our products do not always have [removed: some form of] [added: such] coverage, including simple broad-based contractual coverage, with third-party payors and we frequently experience administrative challenges in obtaining [added: coverage or] reimbursement for our [removed: customers.][added: products.]
If we are unable to obtain adequately broad [added: coverage or] reimbursement [removed: at acceptable prices] for our products or any future products from third-party payors, our revenue may be negatively impacted.
[removed: In January 2017, the] [added: The] Centers for Medicare & Medicaid Services, or CMS, [removed: established a classification of] [added: provides coverage for] “Therapeutic Continuous Glucose Monitors” as durable medical equipment eligible for coverage under Medicare Part B.
Adverse coverage or reimbursement decisions relating to our [removed: products] [added: products, or rescission or limitation of favorable determinations,] by CMS, its Medicare Administrative Contractors, other state, federal or international payors, and/or third-party commercial payors could significantly reduce reimbursement, which could have an impact on the acceptance of, and demand for, our products and the prices that our customers are willing to pay for them.
As of December 31, [removed: 2021,] [added: 2022,] the eight largest private third-party payors, in terms of the number of covered lives, have issued coverage policies for the category of CGM devices.
[removed: However,] [added: Among other things,] people with diabetes without insurance that covers our products [removed: will have to] bear the financial cost of them.
In [added: addition, in] the United States, people with diabetes using existing single-point finger stick devices are generally reimbursed all or part of the product cost by Medicare or other third-party [removed: payors.][added: payors, which may be perceived as more advantageous for consumers.]
[removed: While] [added: Further, while] many third-party payors have adopted some form of coverage policy on CGM devices, in a sizeable percentage of cases, under durable medical equipment benefits, those coverage policies frequently are restrictive and require significant medical documentation and other requirements in order for policy holders to obtain reimbursement, and as a result, we have difficulty improving the efficiency of our customer service group.
[removed: In addition, Medicare, Medicaid, other governmental health programs, health maintenance organizations and other] [added: Nevertheless,] third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new and existing medical devices, and, as a result, they may be restrictive, or they may not cover or provide adequate payment for our products.
We are unable to predict what effect the current or any future healthcare reform will [removed: have on our business, or the effect these matters will have on our customers.]
Our dependence on the commercial success of our current CGM systems makes us particularly susceptible to any cost [added: containment or reduction efforts.]
The development of new products, or novel technologies and services and the enhancement of our current CGM products (including seeking and [added: potentially] obtaining new indications for use), requires significant investment in research and development, intellectual property protection, clinical trials, regulatory approvals and third party reimbursement.
The results of our product development and commercialization efforts may be affected by a range of factors, including our ability to anticipate customer needs, innovate and develop new [removed: products,] [added: products (whether independently or with our partners),] determine a feasible or timely regulatory pathway or approach, and launch those products cost effectively into multiple markets and geographies.
The development and commercial launch timelines for our products depend a great deal on our ability to achieve clinical endpoints and [added: satisfy] regulatory requirements and to overcome technology challenges, and may be delayed due to scheduling issues with patients and investigators, requests from institutional review boards, or inquiries from regulators about our independent and collaborative product development activities, product performance and manufacturing supply constraints, among other factors.
Even if our development and clinical trial efforts [removed: succeed,] [added: appear successful to us and our regulatory submission appears satisfactory to us,] the FDA may [added: disagree and may decide] not [removed: approve] [added: to grant marketing authorization for] the products or may require additional product testing [removed: and] [added: or] clinical trials [added: or other data to be developed and submitted] before approving the products, which would result in product launch delays and additional expense.
[removed: If approved by] [added: Even if a product receives marketing authorization from] the FDA, [removed: the products] [added: it] may not be accepted in the marketplace by physicians and people with diabetes.
In the ordinary course of our [removed: business,] [added: business] we enter into collaborative arrangements [removed: to develop new products and] [added: with third parties] to [removed: pursue] [added: expand into] new markets, [added: including with insulin device manufacturers] such as [removed: our agreements with] Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes and The Ypsomed [removed: Group,] [added: Group] to integrate our CGM technology into their insulin delivery [removed: systems, and our amended agreement with Verily to develop one or more next-generation CGM products.][added: systems.]
Any factors that may limit our partners’ ability to achieve widespread adoption of their systems, including competitive pressures, technological breakthroughs for the treatment or prevention of diabetes, adverse regulatory or legal actions relating to insulin pump products, or changes in [removed: reimbursement rates or policies of third-party payors relating to insulin pumps or similar products, could have an adverse impact on our operating results.]
In the event of such a termination, we may be required to devote additional resources to product development and commercialization, we may need to cancel some development programs and we may face increased [added: competition.]
If and when we receive FDA or other regulators’ [removed: approval] [added: marketing authorization] for, and begin commercialization of, our next-generation CGM systems, we expect most patients will migrate onto those systems.
Notwithstanding our prior experience in marketing and selling our products, we might be unable to successfully expand the commercialization of our existing products or begin commercialization of our next-generation CGM systems on a wide-scale for a number of reasons, [removed: including:][added: including the following:]
- our G6 [removed: system prompts] [added: and G7 systems prompt] the user to replace the sensor no later than the tenth day, which might make it expensive for users;
In addition to the risks outlined above, our G6 [added: and G7] systems are more invasive than many other self-monitored glucose testing systems, including single-point finger stick devices, and people with diabetes may be unwilling to insert a sensor in their body, especially if their current diabetes management involves no more than two finger sticks per day.
If our CGM systems do not achieve and maintain an adequate level of acceptance by people [added: with diabetes, healthcare professionals, including physicians, and third party payors, our future revenue may be reduced and our business may be harmed.]
Our facilities are subject to inspections by the FDA and corresponding state agencies on an ongoing basis, and we must comply with Good Manufacturing Practices and [added: the] FDA Quality [removed: Systems Regulations,] [added: System Regulation,] as well as certain state requirements.
If an event occurs at one of our facilities that results in damage to, [added: restrictions on the use of,] or closure of, one or more of such facilities, or if our distributions from those facilities are limited or restricted in any way, we may be unable to manufacture the relevant products at the previous levels or at all.
Additionally, the majority of our operations are conducted at facilities located in San Diego, [removed: California and] [added: California,] Mesa, [removed: Arizona.][added: Arizona and, beginning in 2023, Penang Malaysia.]
However, a natural or man-made disaster, such as fire, flood, earthquake, act of terrorism, cyber-attack or other disruptive event, such as the [added: ongoing] COVID-19 pandemic or another public health emergency, could cause substantial delays in our operations, damage, destroy or limit our manufacturing equipment, inventory, or records and cause us to incur additional expenses.
In the event our existing manufacturing facilities or equipment are affected by [removed: man-][added: man-made or natural disasters, we may be unable to manufacture products for sale or meet customer demands or sales projections.]
Further, insurance coverage may not be available or successfully secured for loss [added: of] profits or business interruption relating to the COVID-19 pandemic and its impacts.
Our manufacturers and suppliers may also experience or be impacted by equipment malfunction, environmental factors, and public health emergencies including but not limited to the [added: ongoing] COVID-19 pandemic, any of which could delay or impede their ability to meet our demand.
[removed: For supply risks related to the COVID-19 pandemic see our Risk Factor entitled, *“The outbreak of the SARS-Cov-2 virus and its variants and the COVID-19 disease that it causes,] [added: *causes,] or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our manufacturing, commercial operations and sales.”*
Closure of non-essential businesses and shelter-in-place orders occurring in the U.S. and globally as a result of the [added: ongoing] COVID-19 pandemic may also adversely impact our outsourced operations.
Although we have [removed: shifted] [added: enabled] our sales and marketing activity to be conducted virtually and remotely, restrictions in connection with the COVID-19 outbreak may have a substantial impact on our customers and sales cycles and have impacted and/or interrupted our sales and marketing activity.
Nevertheless, coverage and reimbursement-related barriers remain.
CMS has proposed new draft coverage guidelines for CGMs, which if implemented, would have a favorable impact on us.
Currently, Medicare coverage for CGM is only available to Medicare patients who take at least three doses of insulin a day, limiting CGM reimbursement for Medicare beneficiaries with intensive Type 1 and 2 diabetes.
The draft Local Coverage Determination (LCD), if finalized, would extend Medicare CGM coverage to patients who use insulin at least once per day.
Further, the LCD would also allow coverage for patients not taking insulin if the patient has a history of problematic hypoglycemia.
We expect CMS to release the final coverage decision this year.
In December 2021, CMS published a final rule expanding the classification of DME under Medicare Parts B & C to include adjunctive CGMs (i.e., CGMs that do not replace standard blood glucose monitors for treatment decisions) and related supplies.
This final rule expands coverage of CGMs to include a large competitor’s competing device, which may negatively impact our sales.
have on our business, or the effect these matters will have on our customers.
We are susceptible to changes in government-mandated coverage requirements and other controls which could impact access to and affordability of our products.
reimbursement rates or policies of third-party payors relating to insulin pumps or similar products, could have an adverse impact on our operating results.
- expanded coverage opportunities for our competitors’ CGM devices and supplies, including coverage for adjunctive CGMs, increasing competition in the marketplace;
- for people with Type 2 diabetes, current reimbursement from third-party payors is generally limited to people on intensive insulin therapy;
Wildfires are also increasingly more common in southern California and present risk to our manufacturing operations.
Our Arizona facility may confront water supply issues resulting from the ongoing drought in the Western United States and our Malaysia facility may confront issues related to its construction on a reclaimed wetland and the political stability of the Malaysia government.
For supply risks related to the ongoing COVID-19 pandemic see our Risk Factor entitled, *“The outbreak of the SARS-CoV-2 virus and its variants and the COVID-19 disease that it*
We have entered into arrangements with pharmacy organizations in various countries to dispense our products directly to patients.
Because of the competition for their services, we may be unable to enter into new partnerships or otherwise expand our pharmacy network on commercially reasonable terms, if at all.
In addition, we cannot guarantee that our existing pharmacy relationships will continue, or that we will be able to maintain or increase sales volume from these relationships in the future.
Therefore, our
Our competitors manufacturing adjunctive CGMs have also recognized expanded Medicare coverage of their CGM devices and supplies following CMS’ December 2021 final rule expanding the classification of DME under Medicare Parts B & C to include adjunctive CGMs.
These devices now directly compete with our CGM products in the Medicare market.
We continue to take precautions to protect the health and safety of our employees, including monitoring community levels of COVID-19 and masking according to the Center for Disease Control’s recommendations.
Additionally, we may increase our use of administrative and support functions from locations outside the United States.
However, our existing safeguards and any
The FDA may refuse to issue a Certificate to Foreign Government if significant compliance-related concerns are identified.
practices, monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
These frameworks, in addition to similar laws being enacted by other states and counties, impose stringent cybersecurity standards and potentially significant non-compliance penalties, involve the expenditure of significant resources, the investment of significant resources and the investment of significant time and effort to comply.
As these laws and regulations continue develop in the United States and internationally, we may be required to expend significant time and resources in order to update existing processes or implement additional mechanisms as necessary to ensure compliance with such cybersecurity laws.
Certain provisions of the security and privacy regulations
For example, from time-to-time, the OCR issues bulletins that outline its interpretations of HIPAA as applied to specific use cases.
On December 1, 2022, OCR issued a bulletin on the requirements under HIPAA for online tracking technologies (e.g., cookies, pixels) to protect the privacy and security of health information.
This bulletin outlined OCR’s position on the use of online tracking technology vendors, when certain information received by such vendors constitutes protected health information under HIPAA, and accordingly, when business associate agreements must be executed between covered entities, like Dexcom, and such vendors.
Dexcom is assessing its responsibilities under the bulletin and determining its next steps in order to comply with OCR’s guidance in the bulletin.
In addition, other states have, or may, enact similar legislation.
Data transfer risk remains a potential issue as certain Data Protection Authorities continue to raise concerns
about the transfer of data to the United States.
Though a new framework may be put in place, it may be challenged as well.
There are numerous and evolving risks to our cybersecurity and privacy from cyber threat actors.
These cyber threat actors, whether internal of external to the Company, are becoming more frequent, sophisticated and coordinated in their attempts to access data, including third parties with whom the Company conducts business through, without limitation, malicious software; data privacy breaches by employees, insiders or others with authorized access; cyber of phishing-attacks; ransomware; attempts to gain unauthorized access to our data and systems; and other electronic security breaches.
In May 2017, CMS Medicare Administrative Contractors issued a revision to an existing joint Local Coverage Determination, which establishes the Medicare conditions of coverage for therapeutic CGM, including our G5 Mobile and G6 systems.
On October 27, 2020, CMS proposed changes to Medicare Durable Medical Equipment, Prosthetics, Orthotic Devices, and Supplies, or DMEPOS, coverage and payment policies that would expand Medicare coverage for CGM devices and supplies by classifying all CGMs (not just therapeutic CGMs) as DME and establishing payment amounts for these items and related supplies.
CMS finalized its proposal on December 21, 2021, expanding Medicare coverage for all types of CGMs.
CGMs will now be categorized as adjunctive and non-adjunctive (i.e., therapeutic CGMs).
The fee schedule amounts for the newly-covered adjunctive CGMs and related supplies will be established in accordance with existing regulations governing pricing for new DME items without a fee schedule pricing history The expanded coverage for CGMs means that additional manufacturers would be able to obtain Medicare coverage and payment for their CGM devices and some of the new CGM options may be cheaper for Medicare beneficiaries, potentially resulting in decreased sales and resulting revenues.
Effective July 18, 2021, CMS also amended local coverage determination L33822 to allow beneficiaries with diabetes to use CGM when prescribed “multiple daily administrations” of insulin, eliminating the “injection” requirement and the four times per day testing requirement for CGM coverage.
Similarly, in September 2016, Germany’s Federal Joint Committee agreed to provide reimbursement for continuous glucose monitoring systems under certain conditions, which we believe are met by our current CGM systems.
Many of these programs impose documentation and other eligibility requirements that make it more difficult to obtain reimbursement.
containment or reduction efforts.
Our Eli Lilly, Insulet, Novo Nordisk, Verily and Ypsomed collaborations have not yet resulted in a commercial product.
In December 2019, Tandem received FDA approval for its second sensor-augmented insulin delivery system, the t:slim X2™ Insulin Pump with Control-IQ™ technology, which integrates with our G6 system.
competition.
- people with Type 2 diabetes do not generally receive broad reimbursement from third-party payors for their purchase of CGM products in the United States, since many payors require that a policy holder meet specific medical criteria to qualify for reimbursement, which may reduce widespread access to or use of our products;
with diabetes, healthcare professionals, including physicians, and third party payors, our future revenue may be reduced and our business may be harmed.
made or natural disasters, we may be unable to manufacture products for sale or meet customer demands or sales projections.
Moreover our shift of durable medical
equipment sales from our direct sales force to distributors could result in negative impacts on the quality or efficacy of our customer sales and support experience.
In addition, if we do not adequately expand and update certain aging and/or outdated infrastructure that help us, among other things, manage our purchasing and inventory, it could negatively impact our operating results and customer experience.
restrictions resulting from, the COVID-19 pandemic, our supply chain may be continue disrupted, limiting our ability to manufacture our devices.
As a medical device manufacturer, we fall within a “critical essential infrastructure” sector, specifically the “Healthcare/Public Health” sector, and are considered exempt under various stay at home/shelter in place orders, including the California Executive Order N-33-20, or the Stay at Home Order, dated March 19, 2020 that was previously in effect.
Accordingly, our employees in California and other locations continue to work because of the importance of our operations to the health and well-being of citizens in the states in which we operate.
Consistent with these stay at home/shelter in place orders, we implemented telework policies wherever possible for appropriate categories of “nonessential” employees, and appropriate safety measures for “essential” employees that were unable to telework, including social distancing, face covering, and increased sanitation standards.
We also suspended any requirement for an employee to obtain a doctor’s note to be absent from or return to the workplace, and follow the latest guidance from the Center for Disease Control and the Occupational Safety and Health Administration regarding suspension of nonessential travel, self-isolation recommendations for employees returning from certain geographic areas, confirmed reports of any COVID-19 diagnosis among our employees, and the return of such employees to our workplace.
Pursuant to updated guidance from the Equal Employment Opportunity Commission, we are engaging in limited and appropriate inquiries of employees regarding potential COVID-19 exposure, based on the direct threat that such exposure may present to our workforce.
On June 15, 2021, the Governor terminated the executive orders that put into place the Stay Home Order and as well as the framework for a gradual, risk-based reopening of the economy (Executive Order N-60-20, issued on May 4, 2020, which issued the Blueprint for a Safer Economy).
He also phased out the vast majority of executive actions put in place since March 2020 as part of California’s response to the COVID-19 pandemic, leaving a subset of provisions that facilitate the ongoing recovery.
Nonetheless, we continue to take precautions to protect the health and safety of our employees, including contact tracing, requiring masks for onsite employees and providing access to onsite vaccination clinics.
There is growing pressure in many jurisdictions, including the United States, and from multinational organizations such as the Organization for Economic Cooperation and Development, or OECD, and the European Union to amend existing international tax rules in order to render them more responsive to current global business practices.
For example, the OECD has published a package of measures for reform of the international tax rules as a product of its Base Erosion and Profit Shifting, or BEPS, initiative, which was endorsed by the G20 finance ministers.
Many of the initiatives in the BEPS package require amendments to the domestic tax legislation of various jurisdictions.
Separately, the European Union is asserting that a number of country-specific favorable tax regimes and rulings in certain member states may violate, or have violated, European Union law, and may require rebates of some or all of the associated tax benefits to be paid by benefited taxpayers in particular cases.
In 2016, the European Union adopted the "Anti-Tax Avoidance Directive," which requires European Union member states to implement measures to prohibit tax avoidance practices, and Germany published the European Union Anti-Tax Avoidance Directive Implementation Law on June 30, 2021.
We have a significant presence in the European Union, as well as significant sales in the European Union, such that any changes in tax laws in the European Union will impact our business.
The overall impact of such legislation in European Union member states is uncertain, and our business and financial condition could be adversely affected by any laws impacting our tax rate.
In addition, a recession, depression or other
The FDA may refuse to issue a Certificate to Foreign Government in certain instances, including without limitation, during the pendency of any outstanding warning letter.
These laws include foreign, federal and state medical privacy laws, breach notification laws and consumer protection laws.
These frameworks impose stringent cybersecurity standards and potentially significant non-compliance penalties.
The GDPR also requires companies processing personal
For example, following a decision of the Court of Justice of the EU in October 2015, the transfer of personal data to US companies that had certified as members of the US Safe Harbor Scheme was declared invalid.
An excerpt. Shown here: 40 of 191 rewritten, 40 of 102 added and 40 of 105 removed. The counts are complete. For every sentence, read Item 1A. RISK FACTORS in the FY2022 filing and the FY2021 filing.
Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
82 rewritten, 39 added, 23 removed, 126 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
The risks and uncertainties include, among other things, impacts on our business due to health pandemics or other contagious outbreaks, such as the [removed: current] [added: ongoing] COVID-19 pandemic.
The risks and uncertainties that could cause actual results to differ materially are more fully described under “Risk Factors” [removed: and] [added: in Part I, Item 1A of this Annual Report,] elsewhere in this [removed: report] [added: Annual Report,] and in our other reports filed with the SEC.
| | | | We are a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring, or CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. We received approval from the Food and Drug Administration, or FDA, and commercialized our first product in 2006. We launched our latest generation system, the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in [removed: 2018.] [added: 2018 and more recently received marketing clearance from the FDA on the Dexcom G7*®* in December 2022.] Unless the context requires otherwise, the terms “we,” “us,” “our,” the “company,” or “Dexcom” refer to DexCom, Inc. and its subsidiaries. | | | [removed: | | | | | |]
| | | | [removed: | | |] We have built a direct sales organization in [removed: the United States, Australia, Canada, New Zealand,] [added: North America] and certain [removed: countries in Europe] [added: international markets] to call on health care professionals, such as endocrinologists, physicians and diabetes educators, who can educate and influence patient adoption of continuous glucose monitoring. To complement our direct sales efforts, we have entered into distribution arrangements in [removed: the United States, and certain countries in Africa, Asia, Europe, Latin America, and the Middle East, as well as Australia, Canada,] [added: North America] and [removed: New Zealand] [added: several international markets] that allow distributors to sell our products. | | |
| | | | [removed: | | |] Product Development: We plan to develop future generations of technologies that are focused on improved performance and convenience and that will enable intelligent insulin administration. Over the longer term, we plan to continue to develop and improve networked platforms with open architecture, connectivity and transmitters capable of communicating with other devices. We also intend to expand our efforts to accumulate CGM patient data and metrics and apply predictive modeling and machine learning to generate interactive CGM insights that can inform patient behavior. | | |
| | | | [removed: | | |] Partnerships: We also continue to pursue and support development partnerships with insulin pump companies and companies or institutions developing insulin delivery systems, including automated insulin delivery systems. | | |
| | | | [removed: | | |] New Opportunities: We are also exploring how to extend our offerings to other opportunities, including for people with Type 2 diabetes that are non-insulin using, people with pre-diabetes, people who are obese, people who are pregnant, and people in the hospital setting. Eventually, we may apply our technological expertise to products beyond glucose monitoring. | | |
| | | | [removed: | | |] During [removed: 2020 and] [added: 2020,] 2021, [added: and 2022,] we have been subject to challenging social and economic conditions created as a result of the novel strain of coronavirus, [removed: SARS-CoV-2,] [added: SARS-CoV-2 and its variants,] or COVID-19. These conditions continue to create various financial impacts to our operations by necessitating precautions for our personnel to operate safely both in person as well as remotely. Costs incurred include items like incremental payroll costs, consulting support, IT infrastructure and facilities-related costs. | | | | | | | | |
| | | | [removed: | | |] As the result of the COVID-19 pandemic, [added: and in coordination with an FDA communication of enforcement discretion,] we made Dexcom CGM systems available for use in hospital settings and other healthcare [removed: facilities to assist frontline workers.] [added: facilities.] The extent of the impact of the [added: ongoing] COVID-19 pandemic on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers and our sales cycles, employee or industry events, and effect on our vendors, all of which are uncertain and cannot be predicted. The [added: ongoing] COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers or third-party business partners conduct business and as a result, we have experienced moderate disruptions in our global operations. We have experienced and may experience constrained supply or curtailed customer demand, including due to customer loss of private health insurance coverage for our products, that could materially adversely impact our business, results of operations and overall financial performance in future periods. We currently utilize third parties to, among other things, manufacture components and materials for our devices, and to provide services such as sterilization services and we purchase these materials and services from numerous suppliers worldwide. | | | | | | | | |
| | | | [removed: | | |] The [added: ongoing] COVID-19 pandemic has and may continue to have an adverse impact on our manufacturing and distribution capabilities. Disruptions relating to the [added: ongoing] COVID-19 pandemic, including shelter-in-place orders in the U.S. and other countries, could prevent employees, suppliers, distributors, and others from accessing manufacturing facilities and from transporting our products or the components required to manufacture our products. For example, we have experienced some supply chain disruption due to the global restrictions resulting from the [added: ongoing] COVID-19 pandemic in the manufacturing of our next-generation CGM product. Further, worldwide supply chain disruption relating to the [added: ongoing] COVID-19 pandemic has resulted in product shortages that has and may continue to impact our ability to manufacture our devices. As of the filing date of this Annual Report, the extent to which [added: the ongoing] COVID-19 [added: pandemic] may impact our financial condition or results of operations or guidance is uncertain. The effect of the [added: ongoing] COVID-19 pandemic will not be fully reflected in our results of operations and overall financial performance until future periods. See “Risk Factors” in Part I, Item 1A of this Annual Report for further discussion of the possible impact of the [added: ongoing] COVID-19 pandemic on our business. | | | | | | | | |
While our significant accounting policies are described in Note 1 [added: “Organization and Significant Accounting Policies”] to the consolidated financial statements in Part II, Item 8 of this Annual Report, we believe that the following accounting estimates are most critical to a full understanding and evaluation of our reported financial results.
Estimates associated with rebates on products sold through our distributors under pharmacy benefits are the most significant component of our variable consideration estimates and most at risk for material adjustment because of the time delay between the recording of the [removed: accrual estimate] [added: provision] and its ultimate settlement, an interval that generally ranges from 30 to 90 days, but can last up to one year.
An increase or decrease of 1% in our estimate of products sold subject to rebate during [removed: 2021,] [added: 2022,] holding all other assumptions constant, would increase or decrease revenue by approximately [removed: $11.5] [added: $19.1] million.
For more information, see *Revenue Recognition* in Note 1 [added: “Organization and Significant Accounting Policies”] to the consolidated financial statements in Part II, Item 8 of this Annual Report.
We use the asset and liability approach to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities as described in Note 1 [added: “Organization and Significant Accounting Policies”] to the consolidated financial statements in Part II, Item 8 of this Annual Report.
[added: We maintain a valuation allowance on our California research and] development tax [removed: credits, foreign tax credits,] [added: credits] and certain foreign intangible assets, as it is more likely than not that those deferred tax assets will not be realized.
We recognize and measure benefits for uncertain tax positions using a two-step approach as described in Note 1 [added: “Organization and Significant Accounting Policies”] to the consolidated financial statements in Part II, Item 8 of this Annual Report.
| The most important financial indicators that we use to assess our business are [removed: revenue growth,] [added: revenue,] gross profit, operating income, net income, and [added: operating] cash [removed: flow from operations.] [added: flow.] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Key [removed: highlights] [added: Highlights] for fiscal [removed: 2021] [added: 2022] include the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
We ended fiscal [removed: 2021] [added: 2022] with cash, cash equivalents and short-term marketable securities totaling [removed: $2.73] [added: $2.46] billion.
In addition to the general impacts of [removed: COVID-19] [added: current events] on our company as described in the Overview, looking ahead we expect our business could be affected by the following:
- [removed: Growing demand for digital health technologies by both healthcare providers and consumers to reduce costs, empower] [added: An expected interest in empowering] consumers to make better-informed decisions about their own health and [removed: provide] new [added: potential] options for facilitating prevention, early diagnosis of life-threatening diseases, and management of chronic conditions outside of traditional health care settings.
For discussion related to the results of operations and changes in financial condition for fiscal [removed: 2020] [added: 2021] compared to fiscal [removed: 2019] [added: 2020] refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of our [removed: 2020] [added: 2021] Annual Report on Form 10-K, which was filed with the United States Securities and Exchange Commission on February [removed: 11, 2021.][added: 14, 2022.]
| Twelve Months Ended December 31, [removed: 2021] [added: 2022] Compared to Twelve Months Ended December 31, [removed: 2020] [added: 2021] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | Twelve Months Ended December 31, | | | | | | | | | | | | | | | | | | | | | | | | [removed: 2021] [added: 2022] - [removed: 2020] [added: 2021] | | | | | | | | |
| *(In millions, except per share amounts)* | | | [removed: 2021] | | | | | | [removed: % of Revenue (1)] | | | | | | [removed: 2020] [added: (As Adjusted)*] | | | | | | [removed: % of Revenue (1)] | | | | | | [removed: $ Change] | | | | | | [removed: % Change] | | |
| Revenue | | | $ | [removed: 2,448.5] [added: 2,909.8] | | | | | 100 | | % | | | | $ | [removed: 1,926.7] [added: 2,448.5] | | | | | 100 | | % | | | | $ | [removed: 521.8] [added: 461.3] | | | | | [removed: 27] [added: 19] | | % |
| Cost of sales | | | [removed: 768.0] [added: 1,026.7] | | | | | | [removed: 31] [added: 35] | | % | | | | [removed: 646.6] [added: 768.0] | | | | | | [removed: 34] [added: 31] | | % | | | | [removed: 121.4] [added: 258.7] | | | | | | [removed: 19] [added: 34] | | % |
| Gross profit | | | [removed: 1,680.5] [added: 1,883.1] | | | | | | [removed: 68.6] [added: 64.7] | | % | | | | [removed: 1,280.1] [added: 1,680.5] | | | | | | [removed: 66.4] [added: 68.6] | | % | | | | [removed: 400.4] [added: 202.6] | | | | | | [removed: 31] [added: 12] | | % |
| Research and development | | | [removed: 517.1] [added: 484.2] | | | | | | [removed: 21] [added: 17] | | % | | | | [removed: 359.9] [added: 517.1] | | | | | | [removed: 19] [added: 21] | | % | | | | [removed: 157.2] [added: (32.9)] | | | | | | [removed: 44] [added: (6)] | | % |
| Collaborative research and development fee | | | [removed: 87.1] [added: —] | | | | | | [removed: 4] [added: —] | | % | | | | [removed: —] [added: 87.1] | | | | | | [removed: —] [added: 4] | | % | | | | [removed: 87.1] [added: (87.1)] | | | | | | [removed: *] | | |
| Selling, general and administrative | | | [removed: 810.5] [added: 1,000.2] | | | | | | [removed: 33] [added: 34] | | % | | | | [removed: 620.7] [added: 806.8] | | | | | | [removed: 32] [added: 33] | | % | | | | [removed: 189.8] [added: 193.4] | | | | | | [removed: 31] [added: 24] | | % |
| Total operating expenses | | | [removed: 1,414.7] [added: 1,491.9] | | | | | | [removed: 58] [added: 51] | | % | | | | [removed: 980.6] [added: 1,414.7] | | | | | | [removed: 51] [added: 58] | | % | | | | [removed: 434.1] [added: 77.2] | | | | | | [removed: 44] [added: 5] | | % |
| Operating income | | | [removed: 265.8] [added: 391.2] | | | | | | [removed: 11] [added: 13] | | % | | | | [removed: 299.5] [added: 265.8] | | | | | | [removed: 16] [added: 11] | | % | | | | [removed: (33.7)] [added: 125.4] | | | | | | [removed: (11)] [added: 47] | | % |
[removed: | Interest expense | | | (100.3) | | | | | | (4) | | % | | | | (84.7) | | | | | | (4) | | % | | | | (15.6) | | | | | | 18 | | % |][added: Interest expense]
| Loss on extinguishment of debt | | | [removed: (1.5)] [added: —] | | | | | | — | | % | | | | [removed: (5.9)] [added: (0.1)] | | | | | | — | | % | | | | [removed: 4.4] [added: 0.1] | | | | | | [removed: (75)] | | [removed: %] |
[removed: | Income] [added: Income] from equity [removed: investments | | | 11.6 | | | | | | — | | % | | | | — | | | | | | — | | % | | | | 11.6 | | | | | | * | | |][added: investments]
[removed: | Interest] [added: Interest] and other income (expense), [removed: net | | | (1.7) | | | | | | — | | % | | | | 16.1 | | | | | | 1 | | % | | | | (17.8) | | | | | | * | | |][added: net]
| [removed: *] Not meaningful | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
We also incur significant expenses to operate our clinical trials including [added: budgeted] clinical site [added: compensation and] reimbursement, [added: study monitoring and oversight expenses,] clinical trial product and associated travel expenses.
| | | | Who We Are | | |
| | | | Global Presence | | |
| | | | Future Developments | | |
| | | | Impact of Current Events | | | | | | | | |
| | | | In addition, the global supply chain shortages and disruptions are impacting our ability to obtain certain raw materials and components used in our products. We depend on single- or sole-source suppliers to obtain sufficient quantities of these components that are critical to manufacturing our products. Disruptions at these suppliers could lead to a similar disruption in our ability to manufacture products on time to meet consumer demand. In addition, these supply chain constraints may result in higher costs due to a more competitive supply environment. These conditions may impact our gross margin. | | | | | | | | |
| $2.91 billion | | | | | | | | | $1.88 billion | | | | | | | | | $391.2 million | | | | | | | | | $341.2 million | | | | | | | | | $669.5 million | | |
| up 19% from 2021 | | | | | | | | | up 12% from 2021 | | | | | | | | | up 47% from 2021 | | | | | | | | | up 57% from 2021 | | | | | | | | | up 51% from 2021 | | |
- Growing demand for digital health technologies by both healthcare providers and consumers to reduce costs.
- Growing research and interest in the use of CGM technology outside of the ambulatory care setting, including use by hospital systems.
| | | | 2022 | | | | | | % of Revenue (1) | | | | | | 2021 | | | | | | % of Revenue (1) | | | | | | $ Change | | | | | | % Change | | |
| Amortization of intangible assets | | | 7.5 | | | | | | — | | % | | | | 3.7 | | | | | | — | | % | | | | 3.8 | | | | | | | | |
| Interest expense | | | (18.6) | | | | | | (1) | | % | | | | (18.8) | | | | | | (1) | | % | | | | 0.2 | | | | | | (1) | | % |
| Income from equity investments | | | 0.2 | | | | | | — | | % | | | | 11.6 | | | | | | — | | % | | | | (11.4) | | | | | | (98) | | % |
| Interest and other income (expense), net | | | 18.0 | | | | | | 1 | | % | | | | (1.7) | | | | | | — | | % | | | | 19.7 | | | | | | | | |
| Income before income taxes | | | 390.8 | | | | | | 13 | | % | | | | 256.8 | | | | | | 10 | | % | | | | 134.0 | | | | | | 52 | | % |
| Income tax expense | | | 49.6 | | | | | | 2 | | % | | | | 39.9 | | | | | | 2 | | % | | | | 9.7 | | | | | | 24 | | % |
| Net income | | | $ | 341.2 | | | | | 12 | | % | | | | $ | 216.9 | | | | | 9 | | % | | | | $ | 124.3 | | | | | 57 | | % |
| Basic net income per share | | | $ | 0.88 | | | | | | | | | | | $ | 0.56 | | | | | | | | | | | $ | 0.32 | | | | | 57 | | % |
| Diluted net income per share | | | $ | 0.82 | | | | | | | | | | | $ | 0.53 | | | | | | | | | | | $ | 0.29 | | | | | 55 | | % |
| * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements in Part II, Item 8 of this Annual Report for further information. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
In addition, amortization of certain licensing related intangibles are also included in cost of sales.
Amortization of intangible assets
Our amortization expense primarily relates to acquired technology and intellectual property and other acquired intangible assets.
Income from equity investments is comprised of realized gains from the sale of an equity investment.
| Selling, General and Administrative Expense | | | | | | Selling, general and administrative expense increased primarily due to $54.1 million in compensation-related costs most notably due to higher headcount, $26.0 million in advertising and marketing costs due to an increase in worldwide marketing campaigns, $23.0 million in long-lived asset impairment charges, $21.5 million in legal expense related to litigation, $13.0 million in travel and entertainment expenses, and $5.8 million in depreciation expense due to higher property and equipment balances and accelerated depreciation related to business transition activities. | | |
| Interest and Other Income (Expense), Net | | | | | | Interest and other income (expense), net, increased primarily due to $22.1 million in interest income on our short-term marketable securities portfolio, partially offset by foreign currency transaction gains and losses due to the effects of foreign currency fluctuations. The increase in interest income was primarily related to a significant increase in market interest rates, as well as an increase in the average invested balances during 2022 compared to 2021. | | |
markets outside of the United States.
See “Foreign Currency Exchange Risk” in Part II, Item 7A of this Annual Report for more information.
We may use cash to repurchase Dexcom shares or for strategic initiatives that strengthen our foundation for long-term growth.
On July 26, 2022, a duly authorized committee of our Board of Directors authorized a share repurchase program of up to $700.0 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2023.
As of December 31, 2022, approximately $142.3 million remained available for repurchase pursuant to our share repurchase program.
See Note 9 “Employee Benefit Plans and Stockholders’ Equity” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more details.
As of December 31, 2022, we have outstanding senior convertible notes that will mature in December 2023.
We may elect to settle the remaining principal amount outstanding of the 2023 Notes with cash and/ or shares of Dexcom common stock prior to maturity once certain conditions are met.
As of January 1, 2022, for U.S. tax purposes, research and development expenses are required to be capitalized and amortized rather than immediately deducted.
As a result, our annual cash tax payments to the United States Treasury have increased in the current year.
| | | | | | | | | | | | | | | | | | | As Adjusted | | |
| \- | | | $557.7 million in purchases of treasury stock | | | \- | | | $9.9 million in payments for financing leases | | | | | | | | | | | |
| \- | | | $15.6 million in payments for financing leases | | | | | | | | | | | | | | | | | |
| | | | WHO WE ARE | | | | | |  | | |
|  | | | | | | Global Presence | | |
| | | | | | |  | | |
|  | | | | | | Future Developments | | |
|  | | | | | | | | | | | | | | |
|  | | | | | | Impact of COVID-19 Pandemic | | | | | | | | |
Variability reflected in the sensitivity analysis presented below is based on our recent historical experience.
We maintain a valuation allowance on our California research and
| $2.45 billion | | | | | | | | | $1.68 billion | | | | | | | | | $265.8 million | | | | | | | | | $154.7 million | | | | | | | | | $442.5 million | | |
| up 27% from 2020 | | | | | | | | | up 31% from 2020 | | | | | | | | | down 11% from 2020 | | | | | | | | | down 69% from 2020 | | | | | | | | | down 7% from 2020 | | |
*•*Our ability to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, in particular, our next generation G7 CGM system.
| Income before income taxes | | | 173.9 | | | | | | 7 | | % | | | | 225.0 | | | | | | 12 | | % | | | | (51.1) | | | | | | (23) | | % |
| Income tax expense (benefit) | | | 19.2 | | | | | | 1 | | % | | | | (268.6) | | | | | | (14) | | % | | | | 287.8 | | | | | | * | | |
| Net income | | | $ | 154.7 | | | | | 6 | | % | | | | $ | 493.6 | | | | | 26 | | % | | | | $ | (338.9) | | | | | (69) | | % |
| Selling, General and Administrative Expense | | | | | | Selling, general and administrative expense increased primarily due to $84.0 million in additional advertising and marketing costs due to an increase in worldwide marketing campaigns, $60.5 million in additional salaries, bonuses, and payroll-related costs primarily due to higher headcount primarily related to an expansion in our sales force, $16.3 million in additional legal expense related to litigation, $7.4 million of investments in customer experience, partially offset by $12.9 million in lower third party service provider fees due to a change in our channel strategy. | | |
Accordingly, our assessment is that we have no material net exposure to foreign currency exchange rate fluctuations at this time.
Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the Australian Dollar, the British Pound, the Canadian Dollar, the Euro and the Malaysian Ringgit, could adversely affect our financial results, including our revenues, revenue growth rates, gross margins, income and losses as well as assets and liabilities.
We currently engage in hedging transactions to reduce foreign currency risks.
We will continue to monitor and manage our financial exposures due to exchange rate fluctuations as an integral part of our overall risk management program.
See Note 5 “Debt” to
Additional sales-based milestone payments equivalent to 1,288,660 shares of our common stock, calculated based on the $175.0 million initial milestone amount divided by the volume-weighted average trading price during the 15 consecutive days ending on the date of the Restated Collaboration Agreement, may become due and payable by us upon achievement of certain sales-based milestones.
| \- | | | $9.9 million in payments for financing leases | | | + | | | $15.3 million in proceeds from the issuance of common stock under our employee stock plans | | | | | | | | | | | |
| | | | | | | \- | | | $282.6 million cash outflow for repurchase of a portion of our 2022 Notes | | | | | | | | | | | |
An excerpt. Shown here: 40 of 82 rewritten, all 39 added and all 23 removed. The counts are complete. For every sentence, read Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS in the FY2022 filing and the FY2021 filing.
Page headers and footers: 2 lines differ, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]
[removed: ][added: ]
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
8 rewritten, 6 added, 4 removed, 15 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
[removed: The warrant] transactions could have a dilutive effect on our earnings per share to the extent that the price of our common stock during a given quarterly or annual measurement period exceeds the strike price of the warrants.
[removed: However, as our business in markets outside of the United States continues to increase, we] [added: We] will be exposed to [added: additional] foreign currency exchange risk related to our foreign [removed: operations.][added: operations when we begin manufacturing in Malaysia and as our business continues to increase in markets outside of the United States.]
Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies, primarily the Australian Dollar, the British Pound, the Canadian Dollar, the [removed: Euro] [added: Euro,] and the Malaysian Ringgit, could adversely affect our financial results, including [removed: our revenues, revenue growth rates, gross margins,] income and losses as well as assets and [removed: liabilities.][added: liabilities in addition to risks to our revenues, revenue growth rates, and gross profit margins.]
We translate the financial statements of our [removed: foreign] [added: international] subsidiaries with functional currencies other than the U.S. dollar into the U.S. dollar for consolidation using end-of-period exchange rates for assets and liabilities and average exchange rates during each reporting period for results of operations.
We record net gains or losses resulting from the translation of [removed: foreign] [added: these] financial statements and the effect of exchange rate changes on intercompany receivables and payables of a long-term nature as a separate component of stockholders’ equity.
These adjustments will affect net income only upon sale or liquidation of the underlying investment in [removed: foreign] [added: international] subsidiaries.
We [added: also] record exchange rate fluctuations resulting from the translation of the short-term intercompany balances between domestic entities and our [removed: foreign] [added: international] subsidiaries as foreign currency transaction gains or losses and include them in interest and other income (expense), net in our consolidated statements of operations.
[removed: Derivative] [added: The derivative] gains and losses are included in interest and other income (expense), net in our consolidated statements of operations.
The warrant
Historically, our exposure to foreign currency fluctuations is more significant with respect to our revenue than our expenses, as a significant portion of our expenses are denominated in U.S. dollars, such as cost of sales and operating expenses.
Changes in foreign currencies impact currency translation and had a slightly negative effect on our revenues and gross profit margins.
We enter into foreign currency forward contracts to hedge monetary assets and liabilities denominated in foreign currencies.
These forward contracts are not designated as hedging instruments and generally mature in one month.
See Note 3 “Fair Value Measurements” to the consolidated financial statements in Part II, Item 8 of this Annual Report for more information.
Accordingly, our assessment is that we have no material net exposure to foreign currency exchange rate fluctuations at this time.
We occasionally enter into foreign currency forward contracts in order to partially offset the impact from fluctuation of the foreign currency rates.
As of December 31, 2021, we had foreign currency forward contracts outstanding with a notional amount of $40.0 million.
The fair values of these derivatives are based on quoted market prices, which are Level 1 inputs, and the derivative instruments are recorded in other current assets or other current liabilities in our balance sheets consistent with the nature of the instrument at period end.
Item 1. BUSINESS
106 rewritten, 87 added, 71 removed, 459 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
We [added: received FDA marketing authorization and] launched our latest generation system, the Dexcom G6*®* integrated Continuous Glucose Monitoring System, or G6, in [removed: 2018.][added: 2018 and more recently received marketing clearance from the FDA on the Dexcom G7*®* in December 2022.]
Also available on our website are printable versions of our Audit Committee charter, Compensation Committee charter, Nominating and Corporate Governance Committee charter, [added: Technology Committee charter, Corporate Governance Guidelines] and Code of Conduct and Business Ethics.
The G6 was the first type of CGM system permitted by the FDA to be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin [removed: dosing] [added: delivery] systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management.
[added: The G6 Pro has many of same features as the G6] and is intended for healthcare professionals to use with their patients ages two years and up.
Our transmitter is reusable until it reaches the end of its use [removed: life.][added: life, labeled as three months.]
- Continuous glucose readings. Automatically sends glucose readings to a Dexcom receiver or compatible [removed: mobile] [added: display] device every five minutes.
- Mobile app and sharing. Compatibility with mobile device applications allows for sharing glucose information with [added: up to 10] other people for added support and care coordination.
- Customizable alarms and alerts. Personalized alert schedule immediately warns the user of pending dangerous high and low blood [removed: sugars.][added: sugar levels.]
- Finger stick elimination. No finger sticks are needed for calibration or diabetes treatment decisions, consistent with the instructions for [removed: use.][added: use, unless symptoms do not match readings.]
- Predictive low alert. [removed: New alert] [added: Alert] feature intended to predict hypoglycemia before it hits to help avoid dangerous low blood sugar events.
In July 2021, we received FDA [removed: 510(k)] [added: marketing] clearance for [added: an iCGM system incorporating] our Real-Time [removed: API,] [added: Application Programming Interfaces (API),] which [added: is an added software component that] expands connectivity and interoperability of the Dexcom CGM digital [removed: ecosystem.][added: ecosystem, enabling communication of iCGM data to client software intended to receive data through the cloud.]
Dexcom Real-Time API enables [removed: invited] [added: authorized] third-party [added: software] developers to integrate real-time CGM data into their digital health apps and [removed: devices.][added: devices for specific and permitted use cases including non-medical device application, medical device data analysis, iCGM secondary display alarm, active patient monitoring, and treatment decisions.]
In July 2021, we obtained CE Mark approval for our [removed: new] Dexcom ONE CGM system, or Dexcom ONE, which we have launched in [removed: four countries: Bulgaria, Estonia, Latvia and Lithuania.][added: several countries in Europe.]
Dexcom ONE consists of three main components: a [removed: Dexcom ONE] sensor, a [removed: Dexcom ONE] transmitter, and a [added: display device consisting of either the] Dexcom ONE app [removed: as the display device] for users with a compatible mobile [removed: device.][added: device, or a Dexcom ONE receiver.]
The general purpose of these development and commercial relationships is to integrate our technology into the insulin pump or pen product offerings of the respective partner, enabling the partner’s insulin delivery [added: device to receive and display glucose readings from our transmitter and, in]
[removed: device to receive and display glucose readings from our transmitter and, in] some cases, use the glucose readings for semi-automated insulin delivery.
In consideration of Verily’s performance of its obligations under the joint development plan of the Restated Collaboration Agreement, the licenses granted to us and the amendment of the original agreement, we have made [removed: upfront] [added: upfront, incentive,] and [removed: incentive] [added: product regulatory approval milestone] payments, and will make potential additional milestone payments for future [removed: product regulatory approval and] sales-based milestones.
See Note 2 “Development and Other Agreements” to the consolidated financial statements in Part II, Item 8 [added: of this Annual Report] and Exhibit [removed: 10.31] [added: 10.15] of this Annual Report for a further description of the Restated Collaboration Agreement, including the number of shares of stock for milestone payments.
According to JDRF, greater than 60,000 people are diagnosed with Type 1 diabetes each year in the United [removed: States and 5 million people in the U.S. are expected to have Type 1 diabetes by 2050.][added: States.]
According to the CDC, as of [removed: 2017-2018,] [added: 2017-2020,] approximately [removed: 19.3%] [added: 19.7%] of children and adolescents aged 2-19 years, or [removed: 14.4] [added: 14.7] million children, in the United States were obese.
[removed: Childhood] [added: In the United States, the percentage of children and adolescents affected by] obesity has more than [removed: doubled in children and quadrupled in adolescents in] [added: tripled since] the [removed: past 30 years.][added: 1970s.]
The Dexcom [removed: Solution][added: Approach]
Our current target market consists primarily of people with Type 1 and Type 2 diabetes who utilize insulin [removed: pump therapy or who utilize multiple daily insulin injections.][added: therapy.]
We also believe that our CGM systems are beginning to have a positive impact [added: on the broader Type 2 population that does not utilize insulin, a group that we estimate to be approximately 30 million people in the United States alone.]
Although the majority of our revenue has been generated in the United States, we have expanded our operations to include [removed: certain countries] [added: additional markets] in [added: North America,] Africa, [removed: Asia,] [added: Asia Pacific,] Europe, Latin [removed: America,] [added: America] and the Middle [removed: East, as well as Australia, Canada, and New Zealand.][added: East.]
Our current CGM systems offer the following [added: potential] advantages to people with diabetes:
- [added: Potential for] Improved Outcomes. Randomized clinical trials and peer reviewed published data have demonstrated that patients with diabetes who used continuous glucose monitoring devices to help manage their disease experienced significant improvements in glucose control, including when compared to patients relying solely on single-point finger stick measurements (i.e., less time in hypoglycemia and hyperglycemia) and reductions in A1c levels when compared to baseline.
- Access to Real-Time Values, Trend Information and Alerts. [removed: At their fingertips, people] [added: People] with diabetes can view their current glucose value, along with a graphical display of the historical trend information on our receiver or alternate display device.
[removed: To achieve these objectives, we] [added: We] are focusing on the following business [removed: strategies:][added: strategies as we pursue these objectives:]
- [removed: Driving the adoption] [added: Supporting use] of our ambulatory products through a direct sales and marketing effort, as well as key distribution arrangements.
- [removed: Driving additional adoption] [added: Supporting innovation] through technology integration partnerships such as our current partnerships with Eli Lilly, Insulet, Novo Nordisk, Tandem Diabetes, The Ypsomed Group and others globally.
- [removed: Driving increased utilization and adoption of our products through a] [added: Providing] cloud-based data repository platform that enables people with diabetes to aggregate and analyze data from numerous diabetes devices and share the data with their healthcare providers and other individuals involved in their diabetes management and care.
- [removed: Expanding the] [added: Pursuing expansion of] use of our products to other patient care settings and patient demographics, including use for people with Type 2 diabetes who are not on intensive insulin therapy, population health, patient monitoring including in the hospital setting, and people who are pregnant.
After a stabilization [removed: period with the G6,] [added: period,] the user will begin receiving CGM data on his or her mobile device or dedicated receiver through the ten-day usage period.
Our G6 [removed: system has] [added: and G7 systems have] labeling from the FDA and CE Mark permitting their use as a replacement for finger sticks for making therapeutic adjustments.
The disposable [removed: sensor] [added: sensors] contained in the G6 [removed: system is] [added: and G7 systems respectively are each] intended to function for up to ten days, after which the sensor should be replaced.
Proprietary algorithms and software, developed from our extensive database of continuous glucose data from clinical trials, are programmed into the G6 [added: and G7] transmitter to process the glucose data from the sensor, which then sends the processed glucose data to the receiver and displays it on a user-friendly graphical user interface.
With our G6 [removed: system,] [added: and G7 systems,] the functionalities of our proprietary receiver can be obtained through the use of a compatible mobile device, such as an iOS or Android device, and our mobile applications, depending on the patient’s geographic location.
We have gained our technology expertise by [removed: learning to design] [added: developing] implants [removed: that can] [added: designed to] withstand the rigors of functioning within the human body for extended periods of time, [removed: as well as] [added: and designed to address] other [removed: issues] [added: considerations] such as device sealing, miniaturization, durability and sensor geometry.
We are leveraging this technology platform [removed: to enhance] [added: with] the [added: goal of enhancing the] capabilities of our current products (including obtaining expanded indications [removed: of] [added: for] use) and to develop additional CGM products.
- Integration with the world’s largest connected CGM ecosystem (including Apple Watch, Garmin and other digital health apps).
- Medication blocking. Allows for more accurate glucose readings without interference from common medications taken at typical indication doses, such as acetaminophen.
In March 2022, we obtained CE Mark approval for G7.
In December 2022, we obtained marketing authorization from the FDA for the G7 via the 510(k) review process.
Like the G6, the G7 is an iCGM, is classified as a Class II device by the FDA, and is subject to special controls.
The glucose value algorithm, ability to communicate with approved display and mobile devices, and compatibility with CLARITY® are all substantially equivalent in technical performance and capability to the G6.
We are working to obtain reimbursement coverage by Medicare and Medicaid and by commercial insurers in the United States.
Dexcom G7 is now cleared in the United States for all people with diabetes ages two years and older, giving more people than ever access to a powerfully simple diabetes management solution.
With an overall Mean Absolute Relative Difference, or MARD, of 8.2%, Dexcom G7 is the most accurate CGM cleared by the FDA, and is clinically proven to lower A1C (a blood test that provides information about average levels of blood glucose, over the prior three months), reduce hyper- and hypoglycemia and increase time in range.
The G7 carries forward important features of prior generation Dexcom CGM systems:
- Finger stick elimination. No finger sticks are needed for calibration or diabetes treatment decisions, consistent with the instructions for use, unless symptoms do not match readings.
- Continuous glucose readings. Automatically sends glucose readings to a Dexcom receiver or compatible display device every five minutes.
- Mobile app and sharing. Compatibility with mobile device applications allows for sharing glucose information with up to 10 other people for added support and care coordination.
- Designed to integrate with the world’s largest connected CGM ecosystem (including insulin pumps and smart insulin pens, Apple Watch, Garmin and other digital health apps).
- Customizable alarms and alerts. Personalized alert schedule immediately warns the user of pending dangerous high and low blood sugar levels.
- Easy sensor application. Complete redesign of the sensor applicator allows for one-touch, simple self-insertion.
- Predictive low alert. Alert feature intended to predict hypoglycemia before it hits to help avoid dangerous low blood sugar events.
- Extended 10-day disposable sensor.
The G7 also has a number of new or improved features compared to our prior generation devices.
- An even more discreet and low profile. A redesigned transmitter makes for an all-in-one wearable combining our sensor and transmitter that is 60% smaller than the G6, making it even more comfortable and easier to wear under clothing.
- Faster warm up. 30-minute sensor warm up, fastest of any CGM on the market.
- Expanded time to replace sensors. 12-hour grace period to replace finished sensors for a more seamless transition between sessions.
- New mobile app. Redesigned and simplified mobile app with Dexcom Clarity integration.
- Improved alert settings for enhanced discretion at the user’s option.
- Redesigned receiver. The optional receiver is smaller, with a more vibrant, easier to read display.
- New indications for use. Indicated in the United States for wear on the back of the upper arm for ages 2 years and older or the upper buttocks for ages 2-17 years old.
- Less waste. Smaller plastic components and packaging, resulting in less waste than the G6.
Other than the foregoing, the G7 is generally consistent with our prior generation CGM systems in its technical capabilities and its indications.
Since the G7 is classified by the FDA as a Class II device, it is subject to special controls and modifications of, or revisions to, the device may be made under the 510(k) process.
Real-Time API is not permitted for use in environments not currently cleared for the Dexcom CGM System (e.g., hospital inpatient care), and is not intended to be used by automated insulin delivery systems.
We intend to pay the sales-based contingent milestones in shares of our common stock.
This growing diabetes prevalence and its associated health outcomes also result in sobering economic burdens for global health systems.
professionals and patients are knowledgeable about our products and their functionality.
In addition, our direct sales efforts include the use of e-commerce resources in certain international markets where we have not built a sales force.
In December 2021, CMS published a final rule expanding the classification of DME under Medicare Parts B & C to also include adjunctive CGMs (i.e., CGMs do not replace standard blood glucose monitors for treatment decisions) and related supplies.
private third-party payors.
| Sustainability | | | | | | | | | | | | | | |
We believe that taking into account the interests of our various stakeholders – including patients, caregivers, employees, investors, and our communities – enables us to operate in a sustainable manner, supports the success of our business and drives long-term value.
The Nominating and Governance Committee of the Board of Directors oversees and reviews Dexcom’s environmental, social and governance (“ESG”) risks, opportunities, strategies, programs, policies, practices, measures, objectives and performance relating to ESG matters.
Our management-level ESG Steering Committee, which is comprised of the functional leads from our Operations, Human Capital, Finance and Legal departments, is responsible for, among other things, setting the overall strategy with respect to ESG matters (subject to direction from the Chief Executive Officer and oversight of the NG Committee), establishing programs, policies and practices relating to ESG matters (“DexCom’s ESG Program”) and overseeing and monitoring the implementation of DexCom’s ESG Program.
Product Candidates
We are pursuing regulatory approvals for our next generation G7 CGM system.
The G7 is designed with the goal of carrying forward many of the same features as our G6 CGM system and adding several new or improved features, including:
- Reduced size.
A 60% reduction in size of the on-body wearable.
- Fully disposable.
Sensor and transmitter combined into a single, disposable wearable.
- Simple application.
New application process streamlines the number of steps required.
- Faster warmup.
Warmup period expected to be reduced from the current two-hour warmup for G6.
- Reduced packaging waste.
Significant reduction to the product packaging waste profile on a per unit basis.
The G6 Pro has many of same features as the G6
on the broader Type 2 population that does not utilize mealtime insulin, a group that we estimate to be greater than 30 million people in the United States alone.
We directly market our products in the United States, Austria, Canada, Germany, Ireland, Switzerland, and the United Kingdom primarily to endocrinologists, physicians and diabetes educators.
Our campaigns target people with diabetes.
As of December 31, 2021, we had approximately 64,000 square feet of laboratory space and approximately 101,500 square feet of controlled environment rooms.
As of December 31, 2021, those single sources include
In September 2016, Germany’s Federal Joint Committee agreed to provide reimbursement for continuous glucose monitoring systems under certain conditions which we believe we meet.
them from bringing the proprietary rights of third parties to us.
| Corporate Responsibility | | | | | | | | | | | | | | |
We strive to advance the interests of all our stakeholders – including patients, caregivers, employees, investors, and our communities – by operating in an ethical and sustainable way.
Our Nominating and Governance Committee of the Board of Directors oversees and reviews annually (a) our policies and programs concerning (i) corporate social responsibility and (ii) our participation and visibility as a global corporate citizen; (b) our sustainability performance; and (c) the assessment and management of environmental, sustainability and governance risks affecting our business.
- changes in governmental regulations or administrative actions applicable to our trial protocols;
tam” actions.
covered entities), and business associates are subject to direct liability for violation of these provisions.
It remains unclear what, if any, additional modifications will be made to the CPRA by the California legislature or how it will be interpreted.
Other states are also seeking to regulate consumer privacy stringently, and both Virginia and Colorado signed comprehensive privacy legislation into law in 2021.
These laws (the Virginia Consumer Data Protection Act and the Colorado Privacy Act) are set to come into force in 2023 and a number of other state legislatures are actively considering passing similar consumer privacy laws, including those in New York and Washington.
In addition, there has been a recent trend of increased federal and state regulation of payments and other transfers of value provided to healthcare professionals and entities.
As of December 31, 2021, we have approximately 6,300 full-time employees and approximately 700 contract and temporary employees around the globe.
| United States | | | | | | 2,000 | | | | | | 2,500 | | | | | | 4,500 | | | | | | 2,800 | | |
None of our employees are represented by a labor union or covered by a collective bargaining agreement, except for our employees in our Mainz, Germany location that are represented by a Works Council.
We have never experienced any employment-related work stoppages and we consider our employee relations to be good.
We are optimistic about the potential to expand our global workforce and create a more inclusive environment for all of our employees.
We are proud of the additional ground we have gained in 2021 to advance our efforts and the external recognition received in *Forbes* magazine, landing on its *Best Employers for Women*, *Best Employers for Diversity* and *Best in State Employer* lists for the U.S. offices, and the Investors In People Silver Certification awarded to our Dexcom Philippines office.
We established diversity, equity, and inclusion, or DEI, as a corporate objective under our 2021 corporate goal related to the employee experience and commitment.
We have also added several more employee resource groups for our employees globally.
In 2021, we launched an interactive foundational training program on DEI for our managers, in each of Dexcom’s global locations.
An excerpt. Shown here: 40 of 106 rewritten, 40 of 87 added and 40 of 71 removed. The counts are complete. For every sentence, read Item 1. BUSINESS in the FY2022 filing and the FY2021 filing.
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]
Item 3. LEGAL PROCEEDINGS
1 rewritten, 0 added, 0 removed, 5 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
During the [removed: fiscal] year ended December 31, [removed: 2021,] [added: 2022,] we and certain Abbott [added: Diabetes Care, Inc. (“Abbott”)] entities served complaints for patent infringement, validity and other patent related actions against each other in multiple jurisdictions, inside and outside the United States.
Cover and table of contents
35 rewritten, 2 added, 1 removed, 78 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
For the fiscal year ended December 31, [removed: 2021][added: 2022]
As of June 30, [removed: 2021,] [added: 2022,] the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was approximately [removed: $41.1] [added: $29.1] billion based on the closing sales price of [removed: $427.00] [added: $74.53] per share as reported on the Nasdaq Global Select Market.
| Class | | | | | | Outstanding at February [removed: 7, 2022] [added: 2, 2023] | | |
| Common stock, $0.001 par value per share | | | | | | [removed: 97,065,634] [added: 386,413,690] | | |
Portions of the registrant’s definitive proxy statement relating to its [removed: 2022] [added: 2023] Annual Meeting of Stockholders (the “Proxy Statement”) are incorporated by reference in Part III, Items 10 through 14 of this Annual Report on Form 10-K, as specified in the responses to those item numbers.
| [ITEM [removed: 1.](#i15862298089b493198685c5d6204a6cb_13)] [added: 1.](#i6eef640963c94f0198129aab5beef55a_16)] | | | [removed: [Business](#i15862298089b493198685c5d6204a6cb_13)] [added: [Business](#i6eef640963c94f0198129aab5beef55a_16)] | | | [removed: [5](#i15862298089b493198685c5d6204a6cb_13)] [added: [5](#i6eef640963c94f0198129aab5beef55a_16)] | | |
| [ITEM [removed: 1A.](#i15862298089b493198685c5d6204a6cb_19)] [added: 1A.](#i6eef640963c94f0198129aab5beef55a_22)] | | | [Risk [removed: Factors](#i15862298089b493198685c5d6204a6cb_19)] [added: Factors](#i6eef640963c94f0198129aab5beef55a_22)] | | | [removed: [25](#i15862298089b493198685c5d6204a6cb_19)] [added: [27](#i6eef640963c94f0198129aab5beef55a_22)] | | |
| [ITEM [removed: 1B.](#i15862298089b493198685c5d6204a6cb_22)] [added: 1B.](#i6eef640963c94f0198129aab5beef55a_25)] | | | [Unresolved Staff [removed: Comments](#i15862298089b493198685c5d6204a6cb_22)] [added: Comments](#i6eef640963c94f0198129aab5beef55a_25)] | | | [removed: [65](#i15862298089b493198685c5d6204a6cb_22)] [added: [70](#i6eef640963c94f0198129aab5beef55a_25)] | | |
| [ITEM [removed: 2.](#i15862298089b493198685c5d6204a6cb_25)] [added: 2.](#i6eef640963c94f0198129aab5beef55a_28)] | | | [removed: [Properties](#i15862298089b493198685c5d6204a6cb_25)] [added: [Properties](#i6eef640963c94f0198129aab5beef55a_28)] | | | [removed: [66](#i15862298089b493198685c5d6204a6cb_25)] [added: [70](#i6eef640963c94f0198129aab5beef55a_28)] | | |
| [ITEM [removed: 3.](#i15862298089b493198685c5d6204a6cb_28)] [added: 3.](#i6eef640963c94f0198129aab5beef55a_31)] | | | [Legal [removed: Proceedings](#i15862298089b493198685c5d6204a6cb_28)] [added: Proceedings](#i6eef640963c94f0198129aab5beef55a_31)] | | | [removed: [66](#i15862298089b493198685c5d6204a6cb_28)] [added: [70](#i6eef640963c94f0198129aab5beef55a_31)] | | |
| [ITEM [removed: 4.](#i15862298089b493198685c5d6204a6cb_31)] [added: 4.](#i6eef640963c94f0198129aab5beef55a_34)] | | | [Mine Safety [removed: Disclosures](#i15862298089b493198685c5d6204a6cb_31)] [added: Disclosures](#i6eef640963c94f0198129aab5beef55a_34)] | | | [removed: [66](#i15862298089b493198685c5d6204a6cb_31)] [added: [70](#i6eef640963c94f0198129aab5beef55a_34)] | | |
| [ITEM [removed: 5.](#i15862298089b493198685c5d6204a6cb_37)] [added: 5.](#i6eef640963c94f0198129aab5beef55a_40)] | | | [Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity [removed: Securities](#i15862298089b493198685c5d6204a6cb_37)] [added: Securities](#i6eef640963c94f0198129aab5beef55a_40)] | | | [removed: [67](#i15862298089b493198685c5d6204a6cb_37)] [added: [71](#i6eef640963c94f0198129aab5beef55a_40)] | | |
| [ITEM [removed: 6.](#i15862298089b493198685c5d6204a6cb_40)] [added: 6.](#i6eef640963c94f0198129aab5beef55a_43)] | | | [removed: [\[Reserved\]](#i15862298089b493198685c5d6204a6cb_40)] [added: [\[Reserved\]](#i6eef640963c94f0198129aab5beef55a_43)] | | | [removed: [68](#i15862298089b493198685c5d6204a6cb_40)] [added: [72](#i6eef640963c94f0198129aab5beef55a_43)] | | |
| [ITEM [removed: 7.](#i15862298089b493198685c5d6204a6cb_46)] [added: 7.](#i6eef640963c94f0198129aab5beef55a_49)] | | | [Management’s Discussion and Analysis of Financial Condition and Results of [removed: Operations](#i15862298089b493198685c5d6204a6cb_46)] [added: Operations](#i6eef640963c94f0198129aab5beef55a_49)] | | | [removed: [69](#i15862298089b493198685c5d6204a6cb_46)] [added: [73](#i6eef640963c94f0198129aab5beef55a_49)] | | |
| [ITEM [removed: 7A.](#i15862298089b493198685c5d6204a6cb_49)] [added: 7A.](#i6eef640963c94f0198129aab5beef55a_61)] | | | [Quantitative and Qualitative Disclosures about Market [removed: Risk](#i15862298089b493198685c5d6204a6cb_49)] [added: Risk](#i6eef640963c94f0198129aab5beef55a_61)] | | | [removed: [82](#i15862298089b493198685c5d6204a6cb_49)] [added: [86](#i6eef640963c94f0198129aab5beef55a_61)] | | |
| [ITEM [removed: 8.](#i15862298089b493198685c5d6204a6cb_52)] [added: 8.](#i6eef640963c94f0198129aab5beef55a_64)] | | | [Financial Statements and Supplementary [removed: Data](#i15862298089b493198685c5d6204a6cb_52)] [added: Data](#i6eef640963c94f0198129aab5beef55a_64)] | | | [removed: [83](#i15862298089b493198685c5d6204a6cb_52)] [added: [87](#i6eef640963c94f0198129aab5beef55a_64)] | | |
| [ITEM [removed: 9.](#i15862298089b493198685c5d6204a6cb_55)] [added: 9.](#i6eef640963c94f0198129aab5beef55a_67)] | | | [Changes in and Disagreements with Accountants on Accounting and Financial [removed: Disclosure](#i15862298089b493198685c5d6204a6cb_55)] [added: Disclosure](#i6eef640963c94f0198129aab5beef55a_67)] | | | [removed: [83](#i15862298089b493198685c5d6204a6cb_55)] [added: [87](#i6eef640963c94f0198129aab5beef55a_67)] | | |
| [ITEM [removed: 9A.](#i15862298089b493198685c5d6204a6cb_58)] [added: 9A.](#i6eef640963c94f0198129aab5beef55a_70)] | | | [Controls and [removed: Procedures](#i15862298089b493198685c5d6204a6cb_58)] [added: Procedures](#i6eef640963c94f0198129aab5beef55a_70)] | | | [removed: [83](#i15862298089b493198685c5d6204a6cb_58)] [added: [88](#i6eef640963c94f0198129aab5beef55a_70)] | | |
| [ITEM [removed: 9B.](#i15862298089b493198685c5d6204a6cb_61)] [added: 9B.](#i6eef640963c94f0198129aab5beef55a_73)] | | | [Other [removed: Information](#i15862298089b493198685c5d6204a6cb_61)] [added: Information](#i6eef640963c94f0198129aab5beef55a_73)] | | | [removed: [86](#i15862298089b493198685c5d6204a6cb_61)] [added: [90](#i6eef640963c94f0198129aab5beef55a_73)] | | |
| [ITEM [removed: 9C.](#i15862298089b493198685c5d6204a6cb_1422)] [added: 9C.](#i6eef640963c94f0198129aab5beef55a_76)] | | | [Disclosure Regarding Foreign Jurisdictions that Prevent [removed: Inspections](#i15862298089b493198685c5d6204a6cb_1422)] [added: Inspections](#i6eef640963c94f0198129aab5beef55a_76)] | | | [removed: [86](#i15862298089b493198685c5d6204a6cb_1422)] [added: [90](#i6eef640963c94f0198129aab5beef55a_76)] | | |
| [ITEM [removed: 10.](#i15862298089b493198685c5d6204a6cb_67)] [added: 10.](#i6eef640963c94f0198129aab5beef55a_82)] | | | [Directors, Executive Officers and Corporate [removed: Governance](#i15862298089b493198685c5d6204a6cb_67)] [added: Governance](#i6eef640963c94f0198129aab5beef55a_82)] | | | [removed: [86](#i15862298089b493198685c5d6204a6cb_67)] [added: [90](#i6eef640963c94f0198129aab5beef55a_82)] | | |
| [ITEM [removed: 11.](#i15862298089b493198685c5d6204a6cb_70)] [added: 11.](#i6eef640963c94f0198129aab5beef55a_85)] | | | [Executive [removed: Compensation](#i15862298089b493198685c5d6204a6cb_70)] [added: Compensation](#i6eef640963c94f0198129aab5beef55a_85)] | | | [removed: [86](#i15862298089b493198685c5d6204a6cb_70)] [added: [90](#i6eef640963c94f0198129aab5beef55a_85)] | | |
| [ITEM [removed: 12.](#i15862298089b493198685c5d6204a6cb_73)] [added: 12.](#i6eef640963c94f0198129aab5beef55a_88)] | | | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder [removed: Matters](#i15862298089b493198685c5d6204a6cb_73)] [added: Matters](#i6eef640963c94f0198129aab5beef55a_88)] | | | [removed: [86](#i15862298089b493198685c5d6204a6cb_73)] [added: [90](#i6eef640963c94f0198129aab5beef55a_88)] | | |
| [ITEM [removed: 13.](#i15862298089b493198685c5d6204a6cb_76)] [added: 13.](#i6eef640963c94f0198129aab5beef55a_91)] | | | [Certain Relationships and Related Transactions, and Director [removed: Independence](#i15862298089b493198685c5d6204a6cb_76)] [added: Independence](#i6eef640963c94f0198129aab5beef55a_91)] | | | [removed: [86](#i15862298089b493198685c5d6204a6cb_76)] [added: [90](#i6eef640963c94f0198129aab5beef55a_91)] | | |
| [ITEM [removed: 14.](#i15862298089b493198685c5d6204a6cb_79)] [added: 14.](#i6eef640963c94f0198129aab5beef55a_94)] | | | [Principal Accountant Fees and [removed: Services](#i15862298089b493198685c5d6204a6cb_79)] [added: Services](#i6eef640963c94f0198129aab5beef55a_94)] | | | [removed: [86](#i15862298089b493198685c5d6204a6cb_79)] [added: [90](#i6eef640963c94f0198129aab5beef55a_94)] | | |
| [ITEM [removed: 15.](#i15862298089b493198685c5d6204a6cb_85)] [added: 15.](#i6eef640963c94f0198129aab5beef55a_100)] | | | [removed: [Exhibits](#i15862298089b493198685c5d6204a6cb_85)] [added: [Exhibits](#i6eef640963c94f0198129aab5beef55a_100)] and [Financial Statement [removed: Schedules](#i15862298089b493198685c5d6204a6cb_85)] [added: Schedules](#i6eef640963c94f0198129aab5beef55a_100)] | | | [removed: [87](#i15862298089b493198685c5d6204a6cb_85)] [added: [91](#i6eef640963c94f0198129aab5beef55a_100)] | | |
| [ITEM [removed: 16.](#i15862298089b493198685c5d6204a6cb_88)] [added: 16.](#i6eef640963c94f0198129aab5beef55a_103)] | | | [Form 10-K [removed: Summary](#i15862298089b493198685c5d6204a6cb_88)] [added: Summary](#i6eef640963c94f0198129aab5beef55a_103)] | | | [removed: [90](#i15862298089b493198685c5d6204a6cb_88)] [added: [93](#i6eef640963c94f0198129aab5beef55a_103)] | | |
- We are subject to cost-containment efforts by [removed: our] [added: third-party] payors that could result in reduced product pricing and/or sales of our products and cause a reduction in future revenue.
- Although many third-party payors have adopted some form of coverage policy [removed: on] [added: for] continuous glucose monitoring devices, our products do not always have [removed: some form of] [added: such] coverage, including simple broad-based contractual coverage, [removed: with third-party payors] and we frequently experience administrative challenges in obtaining [added: coverage or] reimbursement for our [removed: customers.][added: products.]
If we are unable to [removed: obtain] [added: secure] adequately broad [added: coverage or] reimbursement [removed: at acceptable prices] for our products or any future products from third-party payors, our revenue may be negatively impacted.
- We are subject to complex and evolving U.S. and foreign laws and regulations and other requirements [added: and policy initiatives] regarding privacy, data protection, security, [added: data access] and other matters.
Many of these laws and regulations are subject to change and uncertain [added: or evolving guidance and] interpretation, and could result in claims, changes to our business practices, [added: product development impacts,] monetary penalties, increased cost of operations, or declines in user growth or engagement, or otherwise harm our business.
- Cybersecurity risks and cyber incidents could result in the compromise of confidential data or critical data systems and give rise to potential harm to customers, remediation and other expenses, expose us to [added: costs, negative attention, or] liability under HIPAA, [added: FDA standards and requirements,] consumer protection laws, or other common law theories, subject us to litigation and federal and state governmental inquiries, damage our reputation, and otherwise be disruptive to our business and operations.
- We conduct business in a heavily regulated industry and if we fail to comply with applicable laws and government regulations, we could become subject to [added: government investigation, litigation,] penalties, be excluded from participation in government programs, and/or be required to make significant changes to our operations.
- If we are unable to successfully complete the pre-clinical studies or clinical trials [added: or otherwise develop the data] necessary to support additional [removed: PMA, de novo, or 510(k) applications or supplements,] [added: marketing authorizations,] we may be unable to commercialize [removed: our] [added: additional or modified] CGM [added: candidate] systems under development, which could impair our business, financial condition and operating results.
| | | | [Signatures](#i6eef640963c94f0198129aab5beef55a_106) | | | [94](#i6eef640963c94f0198129aab5beef55a_106) | | |
- Environmental, social and governance, or ESG, regulations, policies, provisions, initiatives and goals, and disclosures related thereto, could expose us to numerous risks, and climate change may have a long-term impact on our business.
| | | | [Signatures](#i15862298089b493198685c5d6204a6cb_91) | | | [91](#i15862298089b493198685c5d6204a6cb_91) | | |
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]
Item 2. PROPERTIES
4 rewritten, 9 added, 4 removed, 2 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
| Location | | | | | | [removed: Approximate Square Feet | | | | | | Purpose | | | | | |] Lease Expiration Dates | | |
[removed: (1)] [added: (2)] Excludes renewals that would be at our option to extend the term of a lease [removed: for approximately 351,400 square feet of space] expiring in [removed: 2023 for two additional three to five-year terms, renewals that would be at our option to extend the term of a lease for approximately 148,400 square feet of space expiring in] 2028 for [removed: one] [added: four] additional five-year [removed: term,] [added: terms] and also excludes renewals that would be at our option to extend the term of a lease [removed: for approximately 92,500 square feet of space] expiring in [removed: 2028] [added: 2030] for two additional five-year terms.
[removed: (2)] [added: (1)] Excludes renewals that would be at our option to extend the term of a lease [removed: for approximately 148,800 square feet of space] expiring in 2028 for [removed: four] [added: one] additional [removed: five-year terms and also excludes renewals that would be at our option] [added: three] to [removed: extend the term of a lease for approximately 485,900 square feet of space expiring in 2030 for two additional] five-year [removed: terms.][added: term.]
We also lease various [added: manufacturing,] administrative, warehouse and customer support real properties throughout the world including North America, Europe, and the Asia-Pacific region.
The following table sets forth the locations of our manufacturing facilities:
| San Diego, California | | | | | | 2028 (1) | | |
| Mesa, Arizona | | | | | | 2030 (2) | | |
| Penang, Malaysia | | | | | | 2082 (3) | | |
(3) Represents 60-year land leases with the state authority expiring at varying dates through 2082.
Our headquarters, research and development, and certain of our manufacturing operations are located in San Diego, California.
As of December 31, 2022, we had approximately 46,800 square feet of laboratory space and approximately 85,200 square feet of controlled environment rooms.
In 2020, we commenced construction of a new facility in Malaysia that we anticipate will add substantial manufacturing capacity.
We expect to begin operations out of the new Malaysia manufacturing facility in 2023.
The following table lists those properties that we believe are material to our business.
| San Diego, CA | | | | | | 698,000 | | | | | | Laboratory, Manufacturing, Research and Development, Warehouse, General and Administrative, Sales and Marketing | | | | | | 2028 (1) | | |
| Mesa, AZ | | | | | | 634,700 | | | | | | General and Administrative, Laboratory, Manufacturing, Warehouse | | | | | | 2030 (2) | | |
During 2020, we entered into a 60-year lease for approximately 28 acres of land in Penang, Malaysia, for the build out of our international manufacturing facility.
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
6 rewritten, 11 added, 4 removed, 12 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
We had fewer than 40 stockholders of record as of December 31, [removed: 2021.][added: 2022.]
There were no unregistered sales of equity securities which have not been previously disclosed in a quarterly report on Form 10-Q or a current report on Form 8-K during the fiscal year ended December 31, [removed: 2021.][added: 2022.]
The graph below compares the cumulative total stockholder return on our common stock with the cumulative total returns on the Nasdaq Composite Index and the Nasdaq Medical Equipment Index over the five-year period ended December 31, [removed: 2021.][added: 2022.]
The graph assumes that $100 was invested in Dexcom common stock and in each of the other indices on December 31, [removed: 2016] [added: 2017] and that all dividends were reinvested.
* $100 invested on December 31, [removed: 2016] [added: 2017] in stock or index, including reinvestment of any dividends.
| | | | | | | December 31, [removed: 2016] [added: 2017] | | | | | | December 31, [removed: 2017] [added: 2018] | | | | | | December 31, [removed: 2018] [added: 2019] | | | | | | December 31, [removed: 2019] [added: 2020] | | | | | | December 31, [removed: 2020] [added: 2021] | | | | | | December 31, [removed: 2021] [added: 2022] | | |
On July 28, 2022, we announced that a duly authorized committee of our Board of Directors authorized and approved a share repurchase program of up to $700 million of our outstanding common stock, with a repurchase period ending no later than June 30, 2023.
As of December 31, 2022, approximately $142.3 million remained available for repurchase pursuant to our share repurchase program.
The following table provides information about purchases by the Company of its shares of common stock during the three months ended December 31, 2022:
| Period | | | | | | Total number of shares purchased | | | | | | Average price paid per share | | | | | | Total number of shares purchased as part of publicly announced program | | | | | | Maximum dollar value of shares that may yet be purchased under the program (in millions) | | |
| 10/01/2022 - 10/31/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | $ | 142.3 | |
| 11/01/2022 - 11/30/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | $ | 142.3 | |
| 12/01/2022 - 12/31/2022 | | | | | | — | | | | | | — | | | | | | — | | | | | | $ | 142.3 | |
See Note 9, “Share Repurchase Program and Treasury Shares” to the consolidated financial statements in Part II, Item 8 of this Annual Report for information about purchases for the year ended December 31, 2022.
| DexCom, Inc. | | | | | | $ | 100.00 | | | | | $ | 208.75 | | | | | $ | 381.15 | | | | | $ | 644.22 | | | | | $ | 935.62 | | | | | $ | 789.27 | |
| Nasdaq Composite | | | | | | $ | 100.00 | | | | | $ | 97.16 | | | | | $ | 132.81 | | | | | $ | 192.47 | | | | | $ | 235.15 | | | | | $ | 158.65 | |
| Nasdaq Medical Equipment | | | | | | $ | 100.00 | | | | | $ | 62.72 | | | | | $ | 61.17 | | | | | $ | 85.34 | | | | | $ | 88.20 | | | | | $ | 59.54 | |
Neither we nor any affiliated purchaser repurchased any of our equity securities during the fiscal year ended December 31, 2021.
| DexCom, Inc. | | | | | | $ | 100.00 | | | | | $ | 96.13 | | | | | $ | 200.67 | | | | | $ | 366.40 | | | | | $ | 619.30 | | | | | $ | 899.41 | |
| Nasdaq Composite | | | | | | $ | 100.00 | | | | | $ | 129.64 | | | | | $ | 125.96 | | | | | $ | 172.17 | | | | | $ | 249.51 | | | | | $ | 304.85 | |
| Nasdaq Medical Equipment | | | | | | $ | 100.00 | | | | | $ | 145.08 | | | | | $ | 161.91 | | | | | $ | 196.50 | | | | | $ | 281.91 | | | | | $ | 332.54 | |
Page headers and footers: 1 line differs, not counted above
Lines that repeat across the filing's pages, such as a footer with the company, form, year and page number. A change here is a change in the page, not in what was disclosed.
[removed: ][added: ]
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
1 rewritten, 0 added, 0 removed, 2 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
The information required is set forth under “Report of Independent Registered Public Accounting Firm,” “Consolidated Balance Sheets,” “Consolidated Statements of Operations,” “ Consolidated Statements of Comprehensive Income,” “Consolidated Statements of Stockholders’ Equity,” “Consolidated Statements of Cash Flows” and “Notes to Consolidated Financial Statements” on pages [removed: [F-2](#i15862298089b493198685c5d6204a6cb_115)] [added: [F-10](#i6eef640963c94f0198129aab5beef55a_130)] to [removed: [F-4](#i15862298089b493198685c5d6204a6cb_163)[0](#i15862298089b493198685c5d6204a6cb_163)] [added: [F-44](#i6eef640963c94f0198129aab5beef55a_199)] of this Annual Report and is incorporated into this Item 8 by reference.
Item 9A. CONTROLS AND PROCEDURES
9 rewritten, 1 added, 5 removed, 34 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
Regulations under the Securities Exchange Act of 1934 require public companies to maintain “disclosure controls and procedures,” which are defined to mean a company’s controls and other procedures that are designed to ensure that information required to be disclosed in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and timely communicated to management, including our Chief Executive Officer and Chief Financial Officer, recorded, processed, [added: summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.]
Based on their evaluation as of December 31, [removed: 2021,] [added: 2022,] our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of such date for this purpose.
Our management, with the participation of the Chief Executive and Chief Financial Officers, assessed the effectiveness of our internal control over financial reporting as of December 31, [removed: 2021.][added: 2022.]
Based on this assessment, our management, with the participation of the Chief Executive and Chief Financial Officers, believes that, as of December 31, [removed: 2021,] [added: 2022,] our internal control over financial reporting is effective based on those criteria.
The effectiveness of our internal control over financial reporting as of December 31, [removed: 2021] [added: 2022] has been audited by Ernst & Young LLP an Independent Registered Public Accounting Firm, as stated in their report which is included herein.
Because of these and other inherent limitations of control systems, we cannot [removed: guaranty] [added: guarantee] that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.
We have audited DexCom, Inc.’s internal control over financial reporting as of December 31, [removed: 2021,] [added: 2022,] based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (the COSO criteria).
In our opinion, DexCom, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, [removed: 2021,] [added: 2022,] based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of DexCom, Inc. as of December 31, [removed: 2021] [added: 2022] and [removed: 2020,] [added: 2021,] the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2021,] [added: 2022,] and the related notes and financial statement schedule listed in the Index at Item 15(a) and our report dated February [removed: 14, 2022] [added: 9, 2023] expressed an unqualified opinion thereon.
February 9, 2023
summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.
As a result of the COVID-19 pandemic, certain employees began working remotely in March 2020.
We have not identified any material changes in our internal control over financial reporting as a result of these changes to the working environment.
We are continually monitoring and assessing the COVID-19 situation to determine any potential impacts on the design and operating effectiveness of our internal controls over financial reporting.
February 14, 2022
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
30 rewritten, 3 added, 35 removed, 22 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
For the three fiscal years ended December 31, [removed: 2021,] [added: 2022,] Schedule II – Valuation and Qualifying Accounts.
| [removed: [4.01](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] [added: [4.01](https://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] | | | | | | [Form of Specimen Certificate for Registrant’s common [removed: stock](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] [added: stock.](http://www.sec.gov/Archives/edgar/data/1093557/000104746905007514/a2153933zex-4_01.htm)] | | | | | | S-1/A | | | | | | 333-122454 | | | | | | March 24, 2005 | | | | | | 4.01 | | | | | | | | | | | |
| [4.02](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm) | | | | | | [Indenture, dated as of November 30, 2018, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.75% Convertible Senior Notes due [removed: 2023)](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] [added: 2023).](http://www.sec.gov/Archives/edgar/data/0001093557/000119312518340482/d667223dex41.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | December 3, 2018 | | | | | | 4.1 | | | | | | | | | | | |
| [4.03](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm) | | | | | | [Indenture, dated as of May 14, 2020, between DexCom, Inc. and U.S. Bank National Association (including the form of 0.25% Convertible Senior Notes due [removed: 2025)](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] [added: 2025).](http://www.sec.gov/Archives/edgar/data/0001093557/000119312520143408/d926678dex41.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | May 15, 2020 | | | | | | 4.1 | | | | | | | | | | | |
| [removed: [10.01](http://www.sec.gov/Archives/edgar/data/1093557/000110465906023702/a06-8554_1ex99d01.htm)] [added: [10.09](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm)] | | | | | | [Office Lease Agreement, dated March 31, 2006, between DexCom, Inc. and Kilroy Realty, [removed: L.P.](http://www.sec.gov/Archives/edgar/data/1093557/000110465906023702/a06-8554_1ex99d01.htm)] [added: L.P., as amended on August 18, 2010 and October 1, 2014.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1009-officel.htm)] | | | | | | [removed: 8-K] | | | | | | [removed: 000-51222] | | | | | | [removed: April 7, 2006] | | | | | | [removed: 99.01] | | | | | | [added: X] | | | | | |
| [removed: [10.03](http://www.sec.gov/Archives/edgar/data/1093557/000119312511179874/dex1026.htm)] [added: [10.10](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1010-amendme.htm)] | | | | | | [Amendment Number One to Non-Exclusive Distribution Agreement, between RGH Enterprises, Inc. and DexCom, Inc., dated March 29, [removed: 2011.](http://www.sec.gov/Archives/edgar/data/1093557/000119312511179874/dex1026.htm)] [added: 2011, as amended on March 28, 2013, December 4, 2013, and April 30, 2016.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1010-amendme.htm)] | | | | | | [removed: 10-Q/A] | | | | | | [removed: 000-51222] | | | | | | [removed: July 1, 2011] | | | | | | [removed: 10.26] | | | | | | [added: X] | | | | | |
| [removed: [10.04](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] [added: [10.01](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm)] | | | | | | [Offer letter between DexCom, Inc. and Kevin Sayer dated May 3, 2011.*](http://www.sec.gov/Archives/edgar/data/1093557/000119312511208448/dex1028.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 3, 2011 | | | | | | 10.28 | | | | | | | | | | | |
| [removed: [10.09](http://www.sec.gov/Archives/edgar/data/1093557/000109355715000040/dxcm-12312014ex1033.htm)] [added: [10.05](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] | | | | | | [removed: [Second] [added: [Third] Amendment to Office Lease between DexCom, Inc. and [removed: Kilroy Realty, L.P.,] [added: John Hancock Life Insurance Company,] dated [removed: October 1, 2014.](http://www.sec.gov/Archives/edgar/data/1093557/000109355715000040/dxcm-12312014ex1033.htm)] [added: January 9, 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February [removed: 25, 2015] [added: 13, 2020] | | | | | | [removed: 10.32] [added: 10.40] | | | | | | | | | | | |
| [removed: [10.11](http://www.sec.gov/Archives/edgar/data/1093557/000109355715000171/exhibit104.htm)] [added: [10.19](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1019-2015emp.htm)] | | | | | | [removed: [Form of Subscription Agreement under 2015] [added: [2015] Employee Stock Purchase [removed: Plan](https://www.sec.gov/Archives/edgar/data/1093557/000109355715000171/exhibit104.htm)] [added: Plan, amended on December 13, 2019 and form of subscription agreement.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1019-2015emp.htm)] | | | | | | [removed: 8-K] | | | | | | [removed: 000-51222] | | | | | | [removed: June 2, 2015] | | | | | | [removed: 10.4] | | | | | | [added: X] | | | | | |
| [removed: [10.12](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] [added: [10.02](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm)] | | | | | | [Sublease between DexCom, Inc. and Entropic Communications, LLC dated February 1, 2016.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1036.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | April 27, 2016 | | | | | | 10.36 | | | | | | | | | | | |
| [removed: [10.13](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1037.htm)] [added: [10.13](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1013-amended.htm)] | | | | | | [Amended and Restated Non-Exclusive Distribution Agreement with Byram Healthcare dated February 1, [removed: 2016.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000511/dxcm03312016ex1037.htm)] [added: 2016.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1013-amended.htm)] | | | | | | [removed: 10-Q] | | | | | | [removed: 000-51222] | | | | | | [removed: April 27, 2016] | | | | | | [removed: 10.37] | | | | | | [added: X] | | | | | |
| [removed: [10.14](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm)] [added: [10.03](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm)] | | | | | | [Industrial Net Lease, Broadway dated April 28, 2016, by and between PRA/LB, L.L.C. and DexCom, Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1039.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 2, 2016 | | | | | | 10.39 | | | | | | | | | | | |
| [removed: [10.15](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016ex1040.htm)] [added: [10.14](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm)] | | | | | | [Standard Form of Agreement dated May 2, 2016, by and between DexCom, Inc. and Skanska USA Building [removed: Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016ex1040.htm)] [added: Inc. and](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm) [Standard Form of Agreement dated](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm) [](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm)[May 1, 2017, by and between DexCom, Inc. and Skanska USA Building Inc.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1014-standar.htm)] | | | | | | [removed: 10-Q] | | | | | | [removed: 000-51222] | | | | | | [removed: August 2, 2016] | | | | | | [removed: 10.40] | | | | | | [added: X] | | | | | |
| [removed: [10.17](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000048/dxcm12312016ex1042.htm)] [added: [10.15](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1015-amendme.htm)] | | | | | | [Amendment No. 1 to Collaboration and License Agreement dated October 25, 2016 by and between DexCom, Inc. and Verily Life Sciences LLC (formerly Google Life Sciences [removed: LLC).](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000048/dxcm12312016ex1042.htm)] [added: LLC), as amended on November 20, 2018.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1015-amendme.htm)] | | | | | | [removed: 10-K] | | | | | | [removed: 000-51222] | | | | | | [removed: February 28, 2017] | | | | | | [removed: 10.42] | | | | | | [added: X] | | | | | |
| [removed: [10.25](https://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1061.htm)] [added: [10.08](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)] | | | | | | [removed: [Amended] [added: [Second Amended] and Restated Credit Agreement dated [removed: December 19, 2018] [added: October 13, 2021] by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative [removed: Agent.](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1061.htm)] [added: Agent.](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February [removed: 21, 2019] [added: 14, 2022] | | | | | | [removed: 10.61] [added: 10.39] | | | | | | | | | | | |
| [removed: [10.27](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] [added: [10.04](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] | | | | | | [Executive Deferred Compensation [removed: Plan](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] [added: Plan.*](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000137/exhibit1002dexcomincexecut.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 4, 2019 | | | | | | 10.02 | | | | | | | | | | | |
| [removed: [10.30](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1038.htm)] [added: [10.12](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1012-distrib.htm)] | | | | | | [Distribution Services Agreement dated November 7, 2015 between DexCom, Inc. and AmerisourceBergen Drug [removed: Corporation.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1038.htm)] [added: Corporation, as amended on November 1, 2018 and December 2, 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1012-distrib.htm)] | | | | | | [removed: 10-K] | | | | | | [removed: 000-51222] | | | | | | [removed: February 13, 2020] | | | | | | [removed: 10.38] | | | | | | [added: X] | | | | | |
| [removed: [10.33](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1041.htm)] [added: [10.18](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm)] | | | | | | [Fourth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated September 9, [removed: 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1041.htm)] [added: 2019, as amended on October 21, 2019 and May 25, 2021, and December 23, 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1018-fourtha.htm)] | | | | | | [removed: 10-K] | | | | | | [removed: 000-51222] | | | | | | [removed: February 13, 2020] | | | | | | [removed: 10.41] | | | | | | [added: X] | | | | | |
| [removed: [10.35](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] [added: [10.06](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] | | | | | | [Form of Indemnity Agreement between Registrant and each of its directors and executive [removed: officers.](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] [added: officers.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex1043doindemn.htm)] | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 11, 2021 | | | | | | 10.43 | | | | | | | | | | | |
| [removed: [10.38](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] [added: [10.07](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] | | | | | | [DexCom Incentive Bonus [removed: Plan](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] [added: Plan.*](http://www.sec.gov/Archives/edgar/data/0001093557/000109355721000084/dxcmex1012021bonusplan.htm)] | | | | | | 8-K | | | | | | 000-51222 | | | | | | March 17, 2021 | | | | | | 10.1 | | | | | | | | | | | |
| [removed: [10.42](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex104210455pac.htm)] [added: [10.20](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1020-officel.htm)] | | | | | | [Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated January 31, [removed: 2020](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex104210455pac.htm)] [added: 2020, as amended on November 17, 2020, and forms of certificates.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1020-officel.htm)] | | | | | | [removed: 10-K] | | | | | | [removed: 000-51222] | | | | | | [removed: February 14, 2022] | | | | | | | | | | | | X | | | | | |
| [removed: [21.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex2101_12312021.htm)] [added: [21.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2101_12312022.htm)] | | | | | | [List of [removed: Subsidiaries](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex2101_12312021.htm)] [added: Subsidiaries.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2101_12312022.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [23.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex2301_12312021.htm)] [added: [23.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2301_12312022.htm)] | | | | | | [Consent of Independent Registered Public Accounting [removed: Firm](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex2301_12312021.htm)] [added: Firm.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex2301_12312022.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| 24.01 | | | | | | Power of Attorney (see signature page of this Form [removed: 10-K)] [added: 10-K).] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [31.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3101.htm)] [added: [31.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3101.htm)] | | | | | | [Certification of Chief Executive Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3101.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3101.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [31.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3102.htm)] [added: [31.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3102.htm)] | | | | | | [Certification of Chief Financial Officer Pursuant to Securities Exchange Act Rule [removed: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3102.htm)] [added: 13a-14(a).](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3102.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [32.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3201.htm)] [added: [32.01](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3201.htm)] | | | | | | [Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).*](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3201.htm)] [added: 13a-14(b).*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3201.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [removed: [32.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3202.htm)] [added: [32.02](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3202.htm)] | | | | | | [Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 and Securities Exchange Act Rule [removed: 13a-14(b).*](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021exhibit3202.htm)] [added: 13a-14(b).*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022exhibit3202.htm)] | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| * | | | Represents a management contract or compensatory [removed: plan.] [added: plan, contract or arrangement.] | | |
| | | | Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. | | |
| [10.11](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1011-adapthe.htm) | | | | | | [Amended and Restated Non-Exclusive Distribution Agreement with Diabetes Management and Supplies, LLC, dated August 10, 2015, as amended on April 7, 2022.](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1011-adapthe.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.16](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1016-severan.htm) | | | | | | [Severance and Change in Control Plan and form of participation agreement.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1016-severan.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| [10.17](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1017-amended.htm) | | | | | | [Amended and Restated 2015 Equity Incentive Plan and forms of award agreements.*](https://www.sec.gov/Archives/edgar/data/1093557/000109355723000024/dxcm12312022ex1017-amended.htm) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | X | | | | | |
| Exhibit Number | | | | | | Exhibit Description | | | | | | Incorporated by Reference | | | | | | | | | | | | | | | | | | | | | | | | Provided Herewith | | | | | |
| Form | | | | | | File No. | | | | | | Date of First Filing | | | | | | Exhibit Number | | | | | | | | | | | | | | | | | | | | | | | |
| [10.02](http://www.sec.gov/Archives/edgar/data/1093557/000119312510248085/dex1027.htm) | | | | | | [First Amendment to Office Lease between DexCom, Inc. and Kilroy Realty, L.P., dated August 18, 2010.](http://www.sec.gov/Archives/edgar/data/1093557/000119312510248085/dex1027.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | November 4, 2010 | | | | | | 10.27 | | | | | | | | | | | |
| [10.05](http://www.sec.gov/Archives/edgar/data/1093557/000109355713000036/dxcm03312013ex1027.htm) | | | | | | [Amendment Number Two to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated March 28, 2013.](http://www.sec.gov/Archives/edgar/data/1093557/000109355713000036/dxcm03312013ex1027.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | May 1, 2013 | | | | | | 10.27 | | | | | | | | | | | |
| [10.06](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1028.htm) | | | | | | [Amendment Number Three to Non-Exclusive Distribution Agreement between RGH Enterprises, Inc. and DexCom, Inc., dated December 4, 2013.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1028.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 20, 2014 | | | | | | 10.28 | | | | | | | | | | | |
| Exhibit Number | | | | | | Exhibit Description | | | | | | Incorporated by Reference | | | | | | | | | | | | | | | | | | | | | | | | Provided Herewith | | | | | |
| Form | | | | | | File No. | | | | | | Date of First Filing | | | | | | Exhibit Number | | | | | | | | | | | | | | | | | | | | | | | |
| [10.07](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1029.htm) | | | | | | [Non-Exclusive Distribution Agreement between DexCom, Inc. and Diabetes Specialty Center, LLC dated October 12, 2009, as amended on September 30, 2010, October 11, 2011, November 14, 2012 and November 1, 2013.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000028/dxcm12312013ex1029.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 20, 2014 | | | | | | 10.29 | | | | | | | | | | | |
| [10.08](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1032.htm) | | | | | | [Amendment No. 5 to Non-Exclusive Distribution Agreement between DexCom, Inc. and Diabetes Specialty Center, LLC, dated March 14, 2014.](http://www.sec.gov/Archives/edgar/data/1093557/000109355714000220/dxcm06302014ex1032.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 6, 2014 | | | | | | 10.32 | | | | | | | | | | | |
| [10.10](http://www.sec.gov/Archives/edgar/data/1093557/000119312515127507/d878103ddef14a.htm#toc878103_89) | | | | | | [2015 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/1093557/000119312515127507/d878103ddef14a.htm#toc878103_89) | | | | | | DEF 14A | | | | | | 000-51222 | | | | | | April 13, 2015 | | | | | | Appendix B | | | | | | | | | | | |
| [10.16](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1041.htm) | | | | | | [Amendment to Non-Exclusive Distribution Agreement dated April 30, 2016 by and between RGH Enterprises, Inc. d/b/a Cardinal Health at Home and DexCom, Inc. ](http://www.sec.gov/Archives/edgar/data/1093557/000109355716000624/dxcm063016exhibit1041.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 2, 2016 | | | | | | 10.41 | | | | | | | | | | | |
| [10.18](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex102.htm) | | | | | | [Severance and Change in Control Plan.](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex102.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 6, 2017 | | | | | | 10.2 | | | | | | | | | | | |
| [10.19](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex103.htm) | | | | | | [Form of Participation Agreement to the Severance and Change in Control Plan.](http://www.sec.gov/Archives/edgar/data/1093557/000119312517195938/d361061dex103.htm) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 6, 2017 | | | | | | 10.3 | | | | | | | | | | | |
| [10.20](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm06302017ex1047.htm) | | | | | | [Standard Form of Agreement dated May 1, 2017, by and between DexCom, Inc. and Skanska USA Building Inc.](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm06302017ex1047.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 1, 2017 | | | | | | 10.47 | | | | | | | | | | | |
| [10.21](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1043.htm) | | | | | | [Form of Indemnity Agreement](http://www.sec.gov/Archives/edgar/data/1093557/000109355717000171/dxcm6302017exhibit1043.htm) | | | | | | 10-Q | | | | | | 000-51222 | | | | | | August 1, 2017 | | | | | | 10.43 | | | | | | | | | | | |
| [10.22](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1051.htm) | | | | | | [Form of RSU Grant Agreement 2015 Plan Global Double Trigger](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1051.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 27, 2018 | | | | | | 10.51 | | | | | | | | | | | |
| [10.23](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1052.htm) | | | | | | [Form of RSU Grant Agreement 2015 Plan Global General](http://www.sec.gov/Archives/edgar/data/1093557/000109355718000018/dxcm12312017exhibit1052.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 27, 2018 | | | | | | 10.52 | | | | | | | | | | | |
| [10.24](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1060.htm) | | | | | | [Amended and Restated Collaboration and License Agreement dated November 20, 2018 by and between DexCom, Inc., Verily Life Sciences LLC (an Alphabet Company) and Verily Ireland Limited.](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000041/dxcm12312018exhibit1060.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 21, 2019 | | | | | | 10.60 | | | | | | | | | | | |
| Exhibit Number | | | | | | Exhibit Description | | | | | | Incorporated by Reference | | | | | | | | | | | | | | | | | | | | | | | | Provided Herewith | | | | | |
| Form | | | | | | File No. | | | | | | Date of First Filing | | | | | | Exhibit Number | | | | | | | | | | | | | | | | | | | | | | | |
| [10.26](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000103/dxcm-2019xdef14a.htm#sc05aea42c3974fe2883a04a695d7a7ff) | | | | | | [Amended and Restated 2015 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1093557/000109355719000103/dxcm-2019xdef14a.htm#sc05aea42c3974fe2883a04a695d7a7ff) | | | | | | 8-K | | | | | | 000-51222 | | | | | | June 4, 2019 | | | | | | 10.01 | | | | | | | | | | | |
| [10.28](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1036.htm) | | | | | | [Form of RSU Grant Agreement 2015 Plan (Board Members - Annual Grant)](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1036.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.36 | | | | | | | | | | | |
| [10.29](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1037.htm) | | | | | | [Form of RSU Grant Agreement 2015 Plan (Board Members - Incoming Grant)](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1037.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.37 | | | | | | | | | | | |
| [10.31](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm) | | | | | | [Amendment to the Distribution Services Agreement between DexCom Inc. and AmerisourceBergen Drug Corporation.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1039.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.39 | | | | | | | | | | | |
| [10.32](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm) | | | | | | [Third Amendment to Office Lease between DexCom, Inc. and John Hancock Life Insurance Company, dated January 9, 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1040.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.40 | | | | | | | | | | | |
| [10.34](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1042.htm) | | | | | | [Fifth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated October 21, 2019.](http://www.sec.gov/Archives/edgar/data/1093557/000109355720000029/dxcm12312019exhibit1042.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 13, 2020 | | | | | | 10.42 | | | | | | | | | | | |
| [10.36](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex10442015espp.htm) | | | | | | [2015 Employee Stock Purchase Plan, amended on December 13, 2019](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex10442015espp.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 11, 2021 | | | | | | 10.44 | | | | | | | | | | | |
| [10.37](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex10452015espp.htm) | | | | | | [Form of Subscription Agreement under 2015 Employee Stock Purchase Plan amended on December 13, 2019](http://www.sec.gov/Archives/edgar/data/1093557/000109355721000024/dxcm12312020ex10452015espp.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 11, 2021 | | | | | | 10.45 | | | | | | | | | | | |
| [10.39](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) | | | | | | [Second Amended and Restated Credit Agreement dated](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) [October 13, 202](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm)[1](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) [by and among DexCom, Inc., Bank of America, Silicon Valley Bank and Union Bank, and JPMorgan Chase Bank, as Administrative Agent.](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm-12312021ex1039locamen.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.40](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1040sixthame.htm) | | | | | | [Sixth Amendment to Office Lease between DexCom, Inc. and Sequence Tech. Center CA LLC, dated May 25, 2021](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1040sixthame.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.41](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1041tenantes.htm) | | | | | | [Tenant Estoppel Certificate - Sequence](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1041tenantes.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.43](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1043firstame.htm) | | | | | | [First Amendment to Office Lease between DexCom, Inc. and GC Pacific Court Center Owner, LLC, dated November 17, 2020](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1043firstame.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.44](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1044tenantes.htm) | | | | | | [Tenant Estoppel Certificate - Pacific Center](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1044tenantes.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| [10.45](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1045tenantsa.htm) | | | | | | [Tenant’s Acceptance of Possession - Pacific Center](https://www.sec.gov/Archives/edgar/data/1093557/000109355722000014/dxcm12312021ex1045tenantsa.htm) | | | | | | 10-K | | | | | | 000-51222 | | | | | | February 14, 2022 | | | | | | | | | | | | X | | | | | |
| | | | Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and were filed separately with the Securities and Exchange Commission. | | |
Item 16. FORM 10-K SUMMARY
435 rewritten, 291 added, 124 removed, 675 unchanged
Read the full itemFY2022 item · filed February 9, 2023FY2021 item · filed February 14, 2022
| Dated: February [removed: 14, 2022] [added: 9, 2023] | | | | | | | | | | | | By: | | | | | | /s/ JEREME M. SYLVAIN | | |
| /s/ KEVIN R. SAYER | | | | | | Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer) | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ JEREME M. SYLVAIN | | | | | | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ MARK G. FOLETTA | | | | | | Lead Independent Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ STEVEN R. ALTMAN | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ NICHOLAS AUGUSTINOS | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ RICHARD A. COLLINS | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ KAREN DAHUT | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ BRIDGETTE P. HELLER | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ BARBARA E. KAHN | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ KYLE MALADY | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ JAY S. SKYLER | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| /s/ ERIC J. TOPOL | | | | | | Director | | | | | | February [removed: 14, 2022] [added: 9, 2023] | | |
| [Report of Independent Registered Public [removed: Accounting Firm](#i15862298089b493198685c5d6204a6cb_97)] [added: A](#i6eef640963c94f0198129aab5beef55a_112)[ccounting Firm](#i6eef640963c94f0198129aab5beef55a_112)] | | | [removed: F-[2](#i15862298089b493198685c5d6204a6cb_97)] [added: F-[2](#i6eef640963c94f0198129aab5beef55a_112)] | | |
| [Consolidated Balance [removed: Sheets](#i15862298089b493198685c5d6204a6cb_100)] [added: Sheets](#i6eef640963c94f0198129aab5beef55a_115)] | | | [removed: F-[4](#i15862298089b493198685c5d6204a6cb_100)] [added: F-[4](#i6eef640963c94f0198129aab5beef55a_115)] | | |
| [Consolidated Statements of [removed: Operations](#i15862298089b493198685c5d6204a6cb_103)] [added: Operations](#i6eef640963c94f0198129aab5beef55a_118)] | | | [removed: F-[5](#i15862298089b493198685c5d6204a6cb_103)] [added: F-[5](#i6eef640963c94f0198129aab5beef55a_118)] | | |
| [Consolidated Statements of Comprehensive [removed: Income](#i15862298089b493198685c5d6204a6cb_106)] [added: Income](#i6eef640963c94f0198129aab5beef55a_121)] | | | [removed: F-[6](#i15862298089b493198685c5d6204a6cb_106)] [added: F-[6](#i6eef640963c94f0198129aab5beef55a_121)] | | |
| [Consolidated Statements of Stockholders’ [removed: Equity](#i15862298089b493198685c5d6204a6cb_109)] [added: Equity](#i6eef640963c94f0198129aab5beef55a_124)] | | | [removed: F-[7](#i15862298089b493198685c5d6204a6cb_109)] [added: F-[7](#i6eef640963c94f0198129aab5beef55a_124)] | | |
| [Consolidated Statements of Cash [removed: Flows](#i15862298089b493198685c5d6204a6cb_112)] [added: Flows](#i6eef640963c94f0198129aab5beef55a_127)] | | | [removed: F-[8](#i15862298089b493198685c5d6204a6cb_112)] [added: F-[8](#i6eef640963c94f0198129aab5beef55a_127)] | | |
| [Notes to Consolidated Financial [removed: Statements](#i15862298089b493198685c5d6204a6cb_115)] [added: Statements](#i6eef640963c94f0198129aab5beef55a_130)] | | | [removed: F-[10](#i15862298089b493198685c5d6204a6cb_115)] [added: F-[10](#i6eef640963c94f0198129aab5beef55a_130)] | | |
We have audited the accompanying consolidated balance sheets of DexCom, Inc. (the Company) as of December 31, [removed: 2021] [added: 2022] and [removed: 2020,] [added: 2021,] the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, [removed: 2021,] [added: 2022,] and the related notes and financial statement schedule listed in the Index at Item 15(a) (collectively referred to as the “consolidated financial statements”).
In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, [removed: 2021] [added: 2022] and [removed: 2020,] [added: 2021,] and the results of its operations and its cash flows for each of the three years in the period ended December 31, [removed: 2021,] [added: 2022,] in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, [removed: 2021,] [added: 2022,] based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated February [removed: 14, 2022] [added: 9, 2023] expressed an unqualified opinion thereon.
The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the [removed: accounts] [added: account] or disclosures to which it relates.
| | | | | | | Our audit procedures also included, among others, evaluating the significant assumptions and the accuracy and completeness of the underlying data used in management’s calculations. This included testing contractual rates, management’s estimates of products sold subject to rebate, and inventory held by third parties at the end of the period, through a combination of underlying data validation by inspection of source documents, agreement to underlying contracts, review for consistency against historical data, and [added: review of] trending of inventory held at third parties versus inventory sold into the channel. In addition, we inspected the results of the Company’s retrospective review analysis of pharmacy rebates [removed: claimed,] [added: claimed and] evaluated the estimates made based on historical [removed: experience and performed sensitivity analyses over the Company's significant assumptions.] [added: experience.] | | |
| *(In millions, except par value data)* | | | [removed: 2021] | | | | | | [removed: 2020] [added: (As Adjusted)*] | | |
| Cash and cash equivalents | | | $ | [added: 642.3 | | | | | $ |] 1,052.6 | | | | | $ | 817.6 | |
| Short-term marketable securities | | | [removed: 1,678.6] [added: 1,813.9] | | | | | | [removed: 1,890.1] [added: 1,678.6] | | |
| Accounts receivable, net | | | [removed: 514.3] [added: 713.3] | | | | | | [removed: 428.5] [added: 514.3] | | |
| Inventory | | | [removed: 357.3] [added: 306.7] | | | | | | [removed: 234.7] [added: 357.3] | | |
| Prepaid and other current assets | | | [removed: 81.6] [added: 192.6] | | | | | | [removed: 53.9] [added: 81.6] | | |
| Total current assets | | | [removed: 3,684.4] [added: 3,668.8] | | | | | | [removed: 3,424.8] [added: 3,684.4] | | |
| Property and equipment, net | | | [removed: 801.8] [added: 1,055.6] | | | | | | [removed: 515.3] [added: 801.8] | | |
| Operating lease right-of-use assets | | | [removed: 88.1] [added: 80.0] | | | | | | [removed: 93.3] [added: 88.1] | | |
| Goodwill | | | [removed: 26.5] [added: 25.7] | | | | | | [removed: 19.3] [added: 26.5] | | |
| Deferred tax assets | | | [removed: 220.8] [added: $] | [added: 216.4] | | | | | [removed: 216.4] [added: $] | [added: 91.3] | | [added: | | | $ | — | | | | | $ | 307.7 | |]
| Accounts payable and accrued liabilities | | | $ | [removed: 573.0] [added: 901.8] | | | | | $ | [removed: 481.1] [added: 573.0] | |
| Accrued payroll and related expenses | | | [removed: 125.2] [added: 134.3] | | | | | | [removed: 114.3] [added: 125.2] | | |
| Short-term operating lease liabilities | | | 20.5 | | | | | | [removed: 16.5] [added: 20.5] | | |
| Deferred revenue | | | [removed: 2.1] [added: 10.1] | | | | | | [removed: 2.2] [added: 2.1] | | |
February 9, 2023
| 2022 | | | | | | 2021 | | | | | |
| Intangibles, net | | | 173.3 | | | | | | 31.5 | | |
| Deferred tax assets | | | 341.2 | | | | | | 290.5 | | |
| Other assets | | | 47.1 | | | | | | 10.5 | | |
| Total assets | | | $ | 5,391.7 | | | | | $ | 4,933.3 | |
| Current portion of long-term senior convertible notes | | | 772.6 | | | | | | — | | |
| Long-term senior convertible notes | | | 1,197.7 | | | | | | 1,981.8 | | |
| Total liabilities | | | 3,259.9 | | | | | | 2,891.2 | | |
| Additional paid-in capital | | | 2,258.1 | | | | | | 2,108.7 | | |
| Retained earnings | | | 479.9 | | | | | | 138.7 | | |
| * We adjusted our 2021 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | |
| Amortization of intangible assets | | | 7.5 | | | | | | 3.7 | | | | | | 2.5 | | |
| Interest expense | | | (18.6) | | | | | | (18.8) | | | | | | (17.7) | | |
| Loss on extinguishment of debt | | | — | | | | | | (0.1) | | | | | | — | | |
| Income before income taxes | | | 390.8 | | | | | | 256.8 | | | | | | 297.9 | | |
| Income tax expense (benefit) | | | 49.6 | | | | | | 39.9 | | | | | | (251.8) | | |
| Net income | | | $ | 341.2 | | | | | $ | 216.9 | | | | | $ | 549.7 | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | |
| *(In millions)* | | | | | | | | | | | | (As Adjusted)* | | | | | | (As Adjusted)* | | |
| Net income | | | | | | $ | 341.2 | | | | | $ | 216.9 | | | | | $ | 549.7 | |
| Comprehensive income | | | | | | $ | 329.1 | | | | | $ | 214.2 | | | | | $ | 550.6 | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | | | | |
| ASU 2020-06 Convertible Debt Full Retrospective Adoption | | | | | | — | | | | | | — | | | | | | (242.3) | | | | | | — | | | | | | 67.8 | | | | | | — | | | | | | (174.5) | | |
| Balance at December 31, 2020 (As Adjusted)* | | | | | | 384.4 | | | | | | 0.4 | | | | | | 1,726.5 | | | | | | 3.2 | | | | | | (78.2) | | | | | | (100.0) | | | | | | 1,551.9 | | |
| Balance at December 31, 2021 (As Adjusted)* | | | | | | 388.0 | | | | | | 0.4 | | | | | | 2,108.7 | | | | | | 0.5 | | | | | | 138.7 | | | | | | (206.2) | | | | | | 2,042.1 | | |
| Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs | | | | | | 2.9 | | | | | | — | | | | | | (189.3) | | | | | | — | | | | | | — | | | | | | 189.2 | | | | | | (0.1) | | |
| Purchases of treasury stock | | | | | | (6.6) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (557.7) | | | | | | (557.7) | | |
| Tax benefit related to Senior Convertible Notes | | | | | | — | | | | | | — | | | | | | (0.4) | | | | | | — | | | | | | — | | | | | | — | | | | | | (0.4) | | |
| Conversions of 2023 Notes | | | | | | 0.4 | | | | | | — | | | | | | 4.2 | | | | | | — | | | | | | — | | | | | | 13.2 | | | | | | 17.4 | | |
| Benefit of note hedge upon conversions of 2023 Notes | | | | | | (0.3) | | | | | | — | | | | | | 33.5 | | | | | | — | | | | | | — | | | | | | (33.5) | | | | | | — | | |
| Capitalization of sales-based milestones | | | | | | — | | | | | | — | | | | | | 152.4 | | | | | | — | | | | | | — | | | | | | — | | | | | | 152.4 | | |
| Balance at December 31, 2022 | | | | | | 386.3 | | | | | | $ | 0.4 | | | | | $ | 2,258.1 | | | | | $ | (11.6) | | | | | $ | 479.9 | | | | | $ | (595.0) | | | | | $ | 2,131.8 | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis on January 1, 2020. All periods presented have also been adjusted to reflect the four-for-one stock split. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| *(In millions)* | | | | | | | | | (As Adjusted)* | | | | | | (As Adjusted)* | | |
| Net income | | | $ | 341.2 | | | | | $ | 216.9 | | | | | $ | 549.7 | |
| Loss on extinguishment of debt | | | — | | | | | | 0.1 | | | | | | — | | |
| | | | | | | | | | (As Adjusted)* | | | | | | (As Adjusted)* | | |
| * We adjusted our 2021 and 2020 amounts to reflect the simplified convertible instruments accounting guidance, which we adopted on a full retrospective basis. Refer to Note 1, “Organization and Significant Accounting Policies,” to the consolidated financial statements for further information. | | | | | | | | | | | | | | | | | |
| December 31, 2022 | | | | | | | | | | | | | | |
February 14, 2022
| Intangibles and other assets, net | | | 42.0 | | | | | | 21.4 | | |
| Total assets | | | $ | 4,863.6 | | | | | $ | 4,290.5 | |
| Total liabilities | | | 2,612.1 | | | | | | 2,464.0 | | |
| Comprehensive income | | | | | | $ | 152.0 | | | | | $ | 494.5 | | | | | $ | 101.9 | |
| Balance at December 31, 2018 | | | | | | 90.0 | | | | | | $ | 0.1 | | | | | $ | 1,560.6 | | | | | $ | 1.5 | | | | | $ | (798.9) | | | | | $ | (100.0) | | | | | $ | 663.3 | |
| Cumulative-effect adjustment from adoption of new lease accounting standard (Note 6) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2.1 | | | | | | — | | | | | | 2.1 | | |
| Realization of tax benefit related to 2023 Note Hedge | | | | | | — | | | | | | — | | | | | | 0.7 | | | | | | — | | | | | | — | | | | | | — | | | | | | 0.7 | | |
| Equity component of 2025 Notes issuance, net of issuance costs | | | | | | — | | | | | | — | | | | | | 289.4 | | | | | | — | | | | | | — | | | | | | — | | | | | | 289.4 | | |
| Balance at December 31, 2020 | | | | | | 96.1 | | | | | | 0.1 | | | | | | 2,125.3 | | | | | | 3.2 | | | | | | (202.1) | | | | | | (100.0) | | | | | | 1,826.5 | | |
| Balance at December 31, 2021 | | | | | | 97.0 | | | | | | 0.1 | | | | | | 2,504.5 | | | | | | 0.5 | | | | | | (47.4) | | | | | | (206.2) | | | | | | 2,251.5 | | |
| Net income | | | $ | 154.7 | | | | | $ | 493.6 | | | | | $ | 101.1 | |
which approximates the related fair values due to the short-term maturities of these instruments.
| Distributor A | | | 28 | | % | | | | 23 | | % | | | | 17 | | % | | | | 16 | | % | | | | 19 | | % |
| Distributor B | | | 12 | | % | | | | 11 | | % | | | | 12 | | % | | | | 11 | | % | | | | 10 | | % |
| Distributor C | | | 21 | | % | | | | 18 | | % | | | | 10 | | % | | | | 13 | | % | | | | 12 | | % |
| Distributor D | | | 18 | | % | | | | 11 | | % | | | | * | | | | | | 13 | | % | | | | * | | |
projections and/or use of a market approach by looking at market values of comparable companies.
The timing of revenue recognition is based on the satisfaction of performance obligations.
Substantially all of the performance obligations associated with our Components are satisfied at a point in time, which typically occurs at shipment of our products.
Terms of direct and distributor orders are generally Freight on Board (FOB) shipping point for U.S. orders or Free Carrier (FCA) shipping point for international orders.
For certain sales transactions, control transfers at delivery of the product to the customer.
The amount and the timing of the cost recognition of such milestones in our financial statements is driven by the accounting for the specific type of equity instrument under ASC 718 that aligns with the terms of the agreement, including any performance conditions.
| Net income | | | | | | $ | 154.7 | | | | | $ | 493.6 | | | | | $ | 101.1 | |
| Basic | | | | | | $ | 1.60 | | | | | $ | 5.23 | | | | | $ | 1.11 | |
| Diluted | | | | | | $ | 1.55 | | | | | $ | 5.06 | | | | | $ | 1.10 | |
| Warrants | | | | | | 2.9 | | | | | | 2.1 | | | | | | — | | |
| Warrants | | | — | | | | | | — | | | | | | 5.2 | | |
| Total | | | 6.8 | | | | | | 7.2 | | | | | | 14.6 | | |
In December 2019, the FASB issued ASU No. 2019-12, *Simplifying the Accounting for Income Taxes,* which is intended to simplify various aspects of the income tax accounting guidance, including requirements such as tax basis step-up in goodwill obtained in a transaction that is not a business combination, ownership changes in investments, and interim-period accounting for enacted changes in tax law.
ASU 2019-12 is effective for public business entities for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted.
Our adoption of ASU 2019-12 at the beginning of the first quarter of 2021 did not have a significant impact on our consolidated financial statements.
We have started the process of evaluating the impact of the full retrospective adoption of ASU 2020-06 on our consolidated financial statements.
We continue to evaluate the effect of ASU 2020-06 on our consolidated financial statements.
Under ASU 2020-06, we will account for our senior convertible notes entirely as a liability and will no longer separately account for them with liability and equity components.
Therefore, we will no longer recognize a debt discount for the value of the conversion option, instead we will record the face value of our senior convertible notes as a liability on our consolidated balance sheet.
The derecognition of the unamortized debt discount will result in an increase in the Long-term senior convertible notes on our consolidated balance sheet.
The elimination of the separation model for the convertible debt instruments is expected to reduce additional paid-in capital.
As the separation of the embedded conversion feature will no longer be amortized into income as interest expense, non-cash interest expense will decrease by the full amount of the previous accretion of debt discount, offset by incremental interest expense from amortization of debt issuance costs that were allocated to the equity component.
We will finalize our retrospective presentation of our historical financial statements under the new standard in connection with our Form 10-Q filings during fiscal year 2022 and our Form 10-K for the fiscal year ending December 31, 2022.
An excerpt. Shown here: 40 of 435 rewritten, 40 of 291 added and 40 of 124 removed. The counts are complete. For every sentence, read Item 16. FORM 10-K SUMMARY in the FY2022 filing and the FY2021 filing.